


Reference Data

(Consolidated Financial Results for Q4 FY2014)



Daiichi-Sankyo

May 14, 2015

Daiichi Sankyo Co., Ltd.

<http://www.daiichisankyo.com>

MEMO

(This page is intentionally left blank)

Contents

1.	Summary of Consolidated Statement of Profit or Loss	P1
2.	Summary of Consolidated Statement of Profit or Loss (only continuing operations)	P2
3.	Revenue by Business Units	P3
4.	Revenue of Global Products	P4
5.	Number of Employees	P5
6.	Management / Financial Indicators	P6
7.	Capital Expenditure and Depreciation and Amortization	P6
8.	Consolidated Statement of Financial Position	P7
9.	Consolidated Statement of Cash Flows	P9
10.	Summary of Product Outlines	P10
11.	Major R&D Pipeline (Innovative pharmaceuticals)	P11

Supplemental Information

Historical Data

1. Summary of Consolidated Statement of Profit or Lo Summary of Consolidated Statement of Profit or Loss <only continuing operations>

JPY Bn	FY2014				JPY Bn	FY2014				FY2015			
	to revenue	Results	YoY	YoY		to revenue	Results	YoY	YoY	to revenue	Forecast	YoY	YoY
[Continuing operations]													
Revenue	100%	919.4	20.2	+2.3%	Revenue	100%	919.4	20.2	+2.3%	100%	920.0	0.6	+0.1%
Cost of sales	35%	323.1	40.2	+14.2%	Cost of sales	35%	323.1	40.2	+14.2%	33%	300.0	-23.1	-7.1%
Gross Profit	65%	596.3	-20.0	-3.2%	Gross Profit	65%	596.3	-20.0	-3.2%	67%	620.0	23.7	+4.0%
SG&A expenses	36%	331.2	8.5	+2.6%	SG&A expenses	36%	331.2	8.5	+2.6%	36%	330.0	-1.2	-0.4%
(General expenses) ^{*1}	34%	313.5	-1.1	-0.3%	(General expenses) ^{*1}	34%	313.5	-1.1	-0.3%				
(Asset related expenses) ^{*2}	1%	8.8	13.6	-	(Asset related expenses) ^{*2}	1%	8.8	13.6	-				
(Loss on restructuring)	1%	8.9	-4.0	-30.9%	(Loss on restructuring)	1%	8.9	-4.0	-30.9%				
R&D expenses	21%	190.7	10.0	+5.5%	R&D expenses	21%	190.7	10.0	+5.5%	21%	190.0	-0.7	-0.3%
Operating Profit	8%	74.4	-38.5	-34.1%	Operating Profit	8%	74.4	-38.5	-34.1%	11%	100.0	25.6	+34.4%
Financial income/expenses		6.4	5.8		Financial income/expenses		6.4	5.8					
Share of profit or loss of investments accounted for using the equity method		-0.9	-0.3		Share of profit or loss of investments accounted for using the equity method		-0.9	-0.3					
Profit before tax	9%	79.9	-33.0	-29.2%	Profit before tax	9%	79.9	-33.0	-29.2%	10%	95.0	15.1	+18.8%
Income taxes		36.4	-10.8		Income taxes		36.4	-10.8					
Profit from continuing operations	5%	43.6	-22.2	-33.8%	Profit for the year	5%	43.6	-22.2	-33.8%				
[discontinued operations]													
Profit from discontinued operations	30%	275.4	287.8	-	Profit attributable to owners of the Company	5%	46.5	-22.3	-32.5%	7%	60.0	13.5	+29.1%
Profit for the year	35%	318.9	265.6	+497.7%									
Profit attributable to owners of the Company	35%	322.1	261.2	+428.6%									
Effective tax rate		45.5%											
Overseas sales ratio results		42.7%											
Currency Rate		FY2014 Results			Currency Rate		FY2014 Results					FY2015 Forecast	
USD/JPY (average)		109.94			USD/JPY (average)		109.94					120.00	
EUR/JPY (average)		138.78			EUR/JPY (average)		138.78					130.00	
INR/JPY (average)		1.81											

Depreciation in JPY against USD, EUR and other currencies positively affected the FY2014 results by 28.5 bil yen in revenue and 4.7 bil yen in operating profit.

Annual impact of one yen change is estimated to affect the group's FY2015 performance by; USD: revenue 1.8 bil yen, operating profit minor / EUR: revenue 0.6 bil yen, operating profit minor

Notes to FY2014 Results Year-on-Year Comparisons

Revenue	{	Japan company, others -5.8 (Nexium +15.1, Teneria +6.0, Pralia +4.2, Mema +3.5, Lixiana +3.2, Inavir +3.1, Loxonin -9.8, Cravit -5.7, Mevalotin -5.3, Vaccines -5.3) Daiichi Sankyo Inc. +1.2 (Olmesartan -5.7, Welchol +5.1, Effient (alliance revenue) +2.1), Luitpold +17.8 (Venofer +3.7, Injectafer +6.3) Daiichi Sankyo Europe -0.4 (Olmesartan -0.4), ASCA company +8.8 Currency impact +28.5 (appreciation of JPY to USD and EUR +23.7, appreciation of JPY to currencies in ASCA region +4.8)
Cost of sales	:	+40.2 (Write-off loss of Zelboraf +35.0)
SG&A expenses	:	+8.5 (Currency impact +14.1 : depreciation of JPY to USD and EUR +12.4, depreciation of JPY to currencies in ASCA region +1.8) Gains from sales of fixed assets -3.3 (-14.2 in FY2013), Civil settlement fee in USA +4.7
R&D expenses	:	+10.0 (Currency impact +5.1 : depreciation of JPY to USD and EUR +5.0, depreciation of JPY to currencies in ASCA region +0.1)
*Loss on restructuring	:	Personnel related costs for business optimization in Japan +13.9 (of which SG&A expenses and R&D expenses +11.7), Daiichi Sankyo Inc. +1.7 (+12.9 Daiichi Sankyo Europe in FY2013)
Financial income/expenses	:	+5.8 Foreign exchange gain etc.
Income taxes	:	-10.8 Decrease of Profit before tax, reversal of deferred tax asset by changing tax rate Dividend received from U3 Pharma was considered as devaluation of book value resulted in tax benefit in FY2013
Profit from discontinued operations	:	+287.8 Gain on merger of subsidiary +360.2 (after tax +278.7)

*1 Incl. A&P expenses, Personnel expenses and other SG&A expenses *2 Incl. Depreciation, Profit or Loss from sales of non-current assets, Impairment loss etc.

At the time of disclosure of this report, the audit procedures for financial statements are in progress in accordance with the Financial Instruments and Exchange Act.

2. Summary of Consolidated Statement of Profit or Loss <only continuing operations>

JPY Bn	Q1		Q2		Q3		Q4		FY2014	
	to revenue	Results	to revenue	Results	to revenue	Results	to revenue	Results	to revenue	Results
Revenue	100%	213.7	100%	215.9	100%	264.8	100%	225.0	100%	919.4
Cost of sales	30%	64.6	31%	66.2	34%	90.1	45%	102.2	35%	323.1
Gross Profit	70%	149.1	69%	149.7	66%	174.7	55%	122.8	65%	596.3
SG&A expenses	35%	74.9	37%	79.3	32%	83.6	42%	93.4	36%	331.2
R&D expenses	19%	41.4	20%	43.5	19%	50.8	24%	55.0	21%	190.7
Operating Profit	15%	32.8	12%	26.9	15%	40.3	-11%	-25.6	8%	74.4
Financial income/expenses		0.2		2.5		5.5		-1.8		6.4
Share of profit or loss of investments accounted for using the equity method		-0.3		-0.5		0.1		-0.2		-0.9
Profit before tax	15%	32.7	13%	28.9	17%	45.8	-12%	-27.5	9%	79.9
Income taxes		11.8		15.1		14.0		-4.6		36.4
Profit for the year	10%	20.9	6%	13.8	12%	31.8	-10%	-22.9	5%	43.6
Profit attributable to owners of the Company	10%	21.6	7%	14.5	12%	32.8	-10%	-22.5	5%	46.5
<u>Effective tax rate</u>		<u>36.1%</u>		<u>52.3%</u>		<u>30.6%</u>		<u>16.7%</u>		<u>45.5%</u>
<u>Overseas sales ratio results</u>		<u>45.2%</u>		<u>41.1%</u>		<u>39.7%</u>		<u>45.3%</u>		<u>42.7%</u>
Currency Rate		Q1		Q2 YTD		Q3 YTD		Q4 YTD		FY2014
		Results		Results		Results		Results		Results
USD/JPY (average)		102.16		103.05		106.88		109.94		109.94
EUR/JPY (average)		140.06		138.91		140.31		138.78		138.78

3. Revenue by Business Units

	FY2014 Plan(Oct)	Q1			Q2			Q3			Q4			FY2014				FY2015 Plan
		Results	YoY	to plan	Results	YoY	to plan	Results	YoY	to plan	Results	YoY	YoY	to plan				
JPY Bn																		
Japan Company (domestic sales)+Vaccine business	480.0	108.0	-1.3%	23%	114.6	-3.0%	24%	145.2	+4.1%	30%	112.7	-5.3%	24%	480.5	-5.5	-1.1%	100%	488.0
Olmotec	79.0	18.7	+12.7%	24%	19.1	-8.8%	24%	20.6	-10.1%	26%	17.9	-4.0%	23%	76.3	-2.8	-3.5%	97%	80.0
Nexium	67.0	15.3	+39.4%	23%	16.8	+28.8%	25%	23.7	+46.1%	35%	13.6	-3.0%	20%	69.3	15.1	+27.9%	104%	74.0
Loxonin	48.0	12.2	-18.0%	26%	13.2	-16.4%	27%	13.3	-18.0%	28%	10.9	-12.7%	23%	49.5	-9.8	-16.5%	103%	44.0
Memary	39.0	7.9	+19.0%	20%	8.9	+14.3%	23%	10.8	+13.6%	28%	9.3	-1.7%	24%	36.8	0.0	+10.5%	94%	47.0
Cravit	27.0	6.9	-9.9%	26%	7.3	-9.7%	27%	8.8	-13.2%	33%	4.9	-36.5%	18%	27.8	-5.7	-16.9%	103%	21.0
Rezaltas	18.0	4.5	+4.2%	25%	4.5	-3.3%	25%	5.0	-2.2%	28%	4.3	+0.9%	24%	18.4	0.0	-0.3%	102%	19.0
Artist	18.0	4.8	-11.7%	27%	4.7	-17.7%	26%	4.7	-22.0%	26%	4.0	-24.7%	22%	18.1	-4.3	-19.1%	101%	17.0
Mevalotin	16.0	4.2	-19.9%	26%	4.1	-29.9%	26%	4.3	-27.7%	27%	3.6	-19.9%	23%	16.2	-5.3	-24.8%	101%	14.0
Omnipaque	17.0	4.2	-10.5%	25%	4.4	-16.4%	26%	4.7	-15.2%	28%	3.9	-6.4%	23%	17.2	-2.5	-12.5%	101%	16.0
Pralia	7.0	1.3	+250.9%	18%	1.7	+200.8%	25%	2.1	+179.6%	31%	2.2	+50.7%	32%	7.3	4.2	+131.8%	105%	10.0
Ranmark	10.0	2.1	+34.0%	21%	2.6	+36.8%	26%	2.9	+23.1%	29%	2.6	+14.9%	26%	10.2	2.1	+26.1%	102%	13.0
Inavir	13.0	0.3	+7.9%	2%	0.0	+38.7%	0%	7.9	+347.0%	61%	8.4	-26.3%	65%	16.6	3.1	+23.4%	128%	12.0
Urief	10.0	2.7	+2.5%	27%	2.9	-1.5%	29%	3.1	-3.8%	31%	2.8	+6.7%	28%	11.5	0.1	+0.7%	115%	11.0
Teneria	not disclosed	1.5	N.M	-	1.8	N.M	-	2.2	N.M	-	2.1	+205.8%	-	7.6	6.0	+390.5%	-	not disclosed
Lixiana	not disclosed	0.1	+2.5%	-	0.1	+7.5%	-	1.9	N.M	-	1.4	+1550.2%	-	3.6	3.2	+792.8%	-	5.0
Efient	not disclosed	0.2	-	-	0.1	-	-	0.2	-	-	0.2	-	-	0.7	0.7	-	-	5.0
Daiichi Sankyo Espha products	not disclosed	3.5	+18.4%	-	3.3	+10.1%	-	4.8	+25.1%	-	3.3	+22.8%	-	14.9	2.4	+19.4%	-	not disclosed
Vaccines business	not disclosed	5.8	-37.5%	-	6.7	-18.5%	-	13.1	-5.7%	-	6.6	+8.3%	-	32.2	-5.3	-14.1%	-	not disclosed
Daiichi Sankyo Healthcare (OTC)	48.0	9.4	-4.0%	20%	13.3	+1.3%	28%	14.3	+1.2%	30%	10.8	-1.9%	23%	47.8	-0.3	-0.5%	100%	48.0
Daiichi Sankyo, Inc. (US)	161.0	41.6	-10.8%	26%	36.5	-8.4%	23%	48.1	+7.9%	30%	46.8	+14.9%	29%	173.0	1.2	+0.7%	108%	140.0
Olmесartan	98.0	25.7	-16.4%	26%	21.5	-17.4%	22%	29.7	+3.6%	30%	29.6	+10.4%	30%	106.6	-5.7	-5.1%	109%	101.0
Benicar/Benicar HCT	71.0	18.9	-20.6%	27%	15.1	-25.1%	21%	21.0	-2.9%	30%	22.0	+8.6%	31%	77.0	-8.9	-10.3%	108%	73.0
Azor	17.0	4.1	-10.6%	24%	3.9	+3.5%	23%	5.4	+22.0%	32%	4.9	+5.2%	29%	18.3	0.9	+4.9%	107%	17.0
Tribenzor	10.0	2.7	+15.6%	27%	2.5	+19.6%	25%	3.3	+25.9%	34%	2.8	+42.2%	28%	11.3	2.3	+25.3%	113%	10.0
Welchol	44.0	11.3	-0.7%	26%	10.5	+8.7%	24%	13.4	+14.6%	30%	12.3	+27.6%	28%	47.4	5.1	+12.1%	108%	9.0
Effient (alliance revenue)	not disclosed	4.2	+6.1%	-	4.2	+16.6%	-	4.6	+21.7%	-	4.5	+11.3%	-	17.6	2.1	+13.7%	-	not disclosed
Savaysa		-	-	-	-	-	-	-	-	-	0.7	-	-	0.7	0.7	-	-	4.0
Luitpold Pharmaceuticals, Inc. (US)	53.0	12.5	+54.3%	24%	14.3	+40.3%	27%	16.2	+69.2%	31%	14.4	+22.5%	27%	57.4	17.8	+44.8%	108%	72.0
Venofer	26.0	7.2	+45.6%	28%	7.0	+3.8%	27%	8.6	+34.0%	33%	5.8	-14.4%	22%	28.6	3.7	+14.9%	110%	27.0
Injectafer	7.0	1.5	-	21%	1.5	+508.2%	21%	2.2	+586.7%	31%	2.6	+239.1%	36%	7.6	6.3	+483.4%	109%	15.0
Daiichi Sankyo Europe GmbH	84.0	24.5	+29.0%	29%	20.0	-6.5%	24%	20.1	-13.8%	24%	18.9	-6.4%	23%	83.5	-0.4	-0.5%	99%	75.0
Olmесartan	66.0	19.7	+37.5%	30%	15.7	-6.8%	24%	14.8	-21.0%	22%	15.0	-4.8%	23%	65.2	-0.4	-0.6%	99%	57.0
Olmotec/Olmotec Plus	38.0	11.1	+13.2%	29%	9.3	-19.5%	25%	8.6	-32.1%	23%	8.7	-16.4%	23%	37.8	-6.8	-15.2%	99%	32.0
Sevikar	17.0	5.3	+77.8%	32%	4.2	+37.7%	25%	3.9	-1.3%	23%	4.1	+18.3%	24%	17.6	4.1	+30.2%	103%	15.0
Sevikar HCT	10.0	3.3	+111.1%	33%	2.1	-1.1%	21%	2.2	+10.7%	22%	2.2	+17.5%	22%	9.9	2.3	+29.9%	99%	9.0
Efient (alliance revenue and others)	not disclosed	1.2	+0.3%	-	1.2	+5.4%	-	1.3	+7.3%	-	1.1	-6.5%	-	4.8	-	+1.7%	-	not disclosed
Asia, South and Central America (ASCA)	64.0	15.1	+18.6%	24%	14.8	+5.0%	23%	18.9	+26.3%	30%	18.6	+10.3%	29%	67.5	8.8	+14.9%	106%	88.0
Daiichi Sankyo China	not disclosed	5.4	+14.3%	-	6.1	+24.6%	-	7.3	+37.3%	-	8.5	+35.7%	-	27.4	6.1	+28.8%	-	not disclosed
Daiichi Sankyo Taiwan	not disclosed	1.2	+9.6%	-	1.1	+4.7%	-	1.2	+9.3%	-	1.3	+11.4%	-	4.9	0.4	+8.8%	-	not disclosed
Daiichi Sankyo Korea	not disclosed	2.7	+51.3%	-	1.7	-23.9%	-	2.0	-23.0%	-	2.5	+1.3%	-	8.9	-0.2	-2.0%	-	not disclosed
Daiichi Sankyo (Thailand)	not disclosed	0.7	+89.2%	-	0.9	+108.0%	-	1.0	+34.1%	-	1.0	+12.3%	-	3.7	1.2	+47.1%	-	not disclosed
Daiichi Sankyo Brasil Farmacêutica	not disclosed	2.3	+34.2%	-	2.0	-1.5%	-	2.6	+31.9%	-	1.5	-16.1%	-	8.4	0.9	+12.0%	-	not disclosed
Daiichi Sankyo Venezuela	not disclosed	1.2	-0.9%	-	1.8	+0.6%	-	2.9	+95.8%	-	2.1	-9.4%	-	8.1	1.2	+17.6%	-	not disclosed

[Reference] Revenue in Local Currency

	FY2014 Plan(Oct)	Q1			Q2			Q3			Q4			FY2014				FY2015 Plan
		Results	YoY	to plan	Results	YoY	to plan	Results	YoY	to plan	Results	YoY	to plan	Results	YoY	YoY	to plan	
USD Mn																		
Daichi Sankyo, Inc. (US)	1,548	407	-13.7%	26%	351	-12.9%	23%	423.0	-4.8%	27%	393.0	-0.6%	25%	1,574	-140	-8.2%	102%	1,167
Olmesartan	942	251	-19.2%	27%	207	-21.4%	22%	262	-8.4%	28%	249	-4.2%	27%	969	-151	-13.5%	103%	842
Benicar/Benicar HCT	683	185	-23.3%	27%	145	-28.9%	21%	185	-14.2%	27%	186	-5.5%	27%	700	-156	-18.2%	103%	608
Azor	163	40	-13.6%	25%	38	-1.5%	23%	48	+8.2%	29%	41	-9.5%	25%	166	-8	-4.4%	102%	142
Tribenzor	96	26	+11.7%	27%	24	+13.8%	25%	30	+11.4%	31%	23	+22.0%	24%	103	13	+14.3%	107%	83
Welchol	423	111	-4.0%	26%	101	+3.5%	24%	117	+1.1%	28%	102	+10.0%	24%	431	9	+2.2%	102%	75
Effient (alliance revenue)	not disclosed	42	+2.5%	-	41	+11.0%	-	40	+6.7%	-	37	-4.7%	-	160	6	+3.7%	-	not disclosed
Savaysa		-	-	-	-	-	-	-	-	-	6	-	-	6	6	-	-	33
USD Mn																		
Luitpold Pharmaceuticals, Inc. (US)	510	122	+49.1%	24%	137	+33.7%	27%	142.0	+49.2%	28%	120.0	+4.3%	24%	522	127	+32.1%	102%	600
Venofer	250	70	+40.8%	28%	68	-1.2%	27%	75	+18.0%	30%	47	-29.1%	19%	260	12	+4.7%	104%	225
Injectafer	67	14	-	21%	14	+478.5%	21%	19	+508.9%	29%	22	+193.4%	33%	69	56	+431.9%	103%	125
EUR Mn																		
Daichi Sankyo Europe GmbH	602	175	+18.8%	29%	146	-11.0%	24%	140.0	-18.1%	23%	141.0	-1.0%	24%	602	-23	-3.6%	100%	577
Olmesartan	473	141	+26.6%	30%	114	-11.2%	24%	103	-25.2%	22%	112	+0.7%	24%	470	-19	-3.8%	99%	438
Olmotec/Olmotec Plus	272	79	+4.2%	29%	68	-23.4%	25%	60	-35.7%	22%	65	-11.5%	24%	272	-59	-17.9%	100%	246
Sevikar	122	38	+63.7%	31%	31	+31.3%	25%	27	-6.8%	22%	30	+24.6%	25%	127	26	+26.1%	104%	115
Sevikar HCT	72	24	+94.3%	33%	15	-5.7%	21%	15	+5.1%	22%	17	+24.1%	23%	71	15	+25.8%	99%	69
Effient (alliance revenue and others)	not disclosed	8	-7.7%	-	8	+0.3%	-	9	+2.6%	-	8	-1.4%	-	34	-1	-1.6%	-	not disclosed

4. Revenue of Global Products

	FY2014 Plan(Oct)	Q1			Q2			Q3			Q4			FY2014				FY2015 Plan
		Results	YoY	to plan	Results	YoY	to plan	Results	YoY	to plan	Results	YoY	to plan	Results	YoY	YoY	to plan	
JPY Bn																		
Olmesartan	284.0	75.8	+3.6%	27%	66.5	-10.7%	23%	77.6	-5.2%	27%	73.7	+1.9%	26%	293.5	-6.6	-2.2%	103%	284.0
Olmotec (JPN)	79.0	18.7	+12.7%	24%	19.1	-8.8%	24%	20.6	-10.1%	26%	17.9	-4.0%	23%	76.3	-2.8	-3.5%	97%	80.0
Rezaltas (JPN)	18.0	4.5	+4.2%	25%	4.5	-3.3%	25%	5.0	-2.2%	28%	4.3	+0.9%	24%	18.4	0.0	-0.3%	102%	19.0
Benicar/Benicar HCT (US)	71.0	18.9	-20.6%	27%	15.1	-25.1%	21%	21.0	-2.9%	30%	22.0	+8.6%	31%	77.0	-8.9	-10.3%	108%	73.0
Azor (US)	17.0	4.1	-10.6%	24%	3.9	+3.5%	23%	5.4	+22.0%	32%	4.9	+5.2%	29%	18.3	0.9	+4.9%	107%	17.0
Tribenzor (US)	10.0	2.7	+15.6%	27%	2.5	+19.6%	25%	3.3	+25.9%	34%	2.8	+42.2%	28%	11.3	2.3	+25.3%	113%	10.0
Olmotec/Olmotec Plus (EU)	38.0	11.1	+13.2%	29%	9.3	-19.5%	25%	8.6	-32.1%	23%	8.7	-16.4%	23%	37.8	-6.8	-15.2%	99%	32.0
Sevikar (EU)	17.0	5.3	+77.8%	32%	4.2	+37.7%	25%	3.9	-1.3%	23%	4.1	+18.3%	24%	17.6	4.1	+30.2%	103%	15.0
Sevikar HCT (EU)	10.0	3.3	+111.1%	33%	2.1	-1.1%	21%	2.2	+10.7%	22%	2.2	+17.5%	22%	9.9	2.3	+29.9%	99%	9.0
Other subsidiaries, export, etc	24.0	7.1	-0.3%	30%	5.8	-3.5%	24%	7.4	+15.0%	31%	6.7	+0.9%	28%	27.0	2.3	+9.4%	113%	29.0
Prasugrel	not disclosed	5.8	-0.5%	-	5.9	+17.2%	-	6.7	+32.5%	-	6.6	+20.2%	-	24.9	2.6	+11.7%	-	not disclosed
Effient alliance revenue (US)	not disclosed	4.2	+6.1%	-	4.2	+16.6%	-	4.6	+21.7%	-	4.5	+11.3%	-	17.6	2.1	+13.7%	-	not disclosed
Effient alliance revenue and others (EU)	not disclosed	1.2	+0.3%	-	1.2	+5.4%	-	1.3	+7.3%	-	1.1	-6.5%	-	4.8	0.1	+1.7%	-	not disclosed
Effient (JPN)	not disclosed	0.2	-	-	0.1	-	-	0.2	-	-	0.2	-	-	0.7	0.7	-	-	5.0
Other subsidiaries, export, etc	not disclosed	0.2	-60.6%	-	0.4	+12.3%	-	0.5	-51.0%	-	0.8	+199.3%	-	1.9	-0.3	-12.2%	-	not disclosed
Edoxaban		0.1	+2.5%	-	0.1	+7.5%	-	1.9	+1452.7%	-	2.1	+2352.0%	-	4.3	3.9	+967.0%	-	9.0
Lixiana (JPN)		0.1	+2.5%	-	0.1	+7.5%	-	1.9	+1452.7%	-	1.4	+1550.2%	-	3.6	3.2	+792.8%	-	5.0
Savaysa (US)		-	-	-	-	-	-	-	-	-	0.7	-	-	0.7	0.7	-	-	4.0

5. Number of Employees

	Mar 2014 Results	Jun 2014 Results	Sep 2014 Results	Dec 2014 Results	Mar 2015 Results
Total Number of Employees	32,791	32,725	32,617	32,823	16,428
Japan	9,145	9,290	9,201	9,171	8,543
Overseas	23,646	23,435	23,416	23,652	7,885
Daiichi Sankyo Group	17,256	17,362	17,298	17,239	16,428
Ranbaxy Group	15,535	15,363	15,319	15,584	-

6. Management / Financial Indicators

	FY2013 Results	FY2014 Q2 YTD Results	FY2014 Results	FY2015 Forecast
Management Indicators				
Basic earnings per share	86.6 Yen	71.5 Yen	457.6 Yen	85.2 Yen
Dividend per share	60.0 Yen	30.0 Yen	60.0 Yen	70.0 Yen
Dividend payout ratio (Consolidated)	69.3 %	42.0 %	13.1 %	82.1 %
Return on equity attributable to owners of the Company	6.5 %	5.0 %	28.2 %	
Ratio of dividends to equity attributable to owners of the Company	4.5 %	2.1 %	3.7 %	
Equity per share attributable to owners of the Company	1,392.0 Yen	1,467.0 Yen	1,852.3 Yen	
Ratio of equity attributable to owners of the Company to total assets	52.9 %	56.2 %	65.8 %	
Total number of common shares	704 million	704 million	704 million	
Share price at end of period	1,738 Yen	1,721 Yen	1,907 Yen	
Market value	1,223.5 JPY Bn	1,211.6 JPY Bn	1,342.6 JPY Bn	
Financial Indicators				
Total assets	1,854.0 JPY Bn	1,838.1 JPY Bn	1,982.3 JPY Bn	
Current assets	990.6 JPY Bn	931.6 JPY Bn	785.3 JPY Bn	
*1 Liquidity on hand	507.3 JPY Bn	439.0 JPY Bn	376.1 JPY Bn	
Debt with interest	426.8 JPY Bn	362.1 JPY Bn	224.6 JPY Bn	
Net Cash	80.5 JPY Bn	76.9 JPY Bn	151.5 JPY Bn	
Equity capital	979.9 JPY Bn	1,032.7 JPY Bn	1,304.1 JPY Bn	
Cash flows from operating activities	37.3 JPY Bn	56.8 JPY Bn	142.8 JPY Bn	
Cash flows from investing activities	-161.4 JPY Bn	25.8 JPY Bn	-21.3 JPY Bn	
Cash flows from financial activities	100.3 JPY Bn	-92.0 JPY Bn	-132.2 JPY Bn	
*2 Free cash flows	-124.1 JPY Bn	82.6 JPY Bn	121.5 JPY Bn	
Cash and cash equivalents at the end of the year	183.1 JPY Bn	180.3 JPY Bn	189.4 JPY Bn	
Others				
Number of consolidated subsidiaries	96	98	55	

*1 Current deposits + marketable securities + investment securities, etc

*2 Cash flows from operating activities and investing activities

7. Capital Expenditure and Depreciation and Amortization

	FY2013 Results	FY2014 Q2 YTD Results	FY2014 Results	FY2015 Plan
Capital expenditure	49.2 JPY Bn	17.7 JPY Bn	36.3 JPY Bn	30.3 JPY Bn
Depreciation and amortization	51.5 JPY Bn	25.6 JPY Bn	42.0 JPY Bn	41.9 JPY Bn
Property, plant and equipment	30.5 JPY Bn	16.1 JPY Bn	27.0 JPY Bn	
Intangible assets	21.0 JPY Bn	9.5 JPY Bn	15.1 JPY Bn	

8. Consolidated Statement of Financial Position

(Billions of yen)

	Mar 2014		Mar 2015	YoY DS Group	Notes
	Consolidated	DS Group			
Assets					
Current assets					
Cash and cash equivalents	183.1	161.7	189.4	27.7	
Trade and other receivables	269.2	226.8	241.5	14.8	
Other financial assets	324.2	317.7	186.5	-131.3	Daiichi Sankyo -164.9 Bn
Inventories	189.4	141.9	150.1	8.2	
Other current assets	24.8	22.2	14.7	-7.5	
Subtotal	990.6	870.3	782.2	-88.1	
Assets held for sale	-	-	3.2	3.2	
Total current assets	990.6	870.3	785.3	-85.0	
Non-current assets					
Property, plant and equipment	316.3	259.2	266.5	7.3	
Goodwill	85.5	45.0	71.4	26.4	
Intangible assets	171.4	146.1	199.4	53.3	Newly added +89.9 Bn
Investments accounted for using the equity method	2.6	2.3	1.3	-1.0	
Other financial assets	141.6	224.6	593.9	369.4	Gain on merger of subsidiary +338.8 Bn
Deferred tax assets	122.6	87.5	45.3	-42.2	
Other non-current assets	23.5	19.2	19.1	-0.1	
Total non-current assets	863.4	783.8	1,197.0	413.1	
Total assets	1,854.0	1,654.1	1,982.3	328.2	

(Billions of yen)

	Mar 2014		Mar 2015	YoY	Notes
	Consolidated	DS Group		DS Group	
Liabilities and equity					
Current liabilities					
Trade and other payables	245.4	210.0	235.5	25.6	
Bonds and borrowings	160.3	90.0	20.0	-70.0	Daiichi Sankyo -70.0 Bn (Payment and Redemption -90.0 Bn, Transfer from non-current liabilities +20.0 Bn)
Other financial liabilities	15.1	0.9	7.6	6.7	
Income taxes payable	5.6	4.2	7.8	3.6	
Provisions	22.7	19.0	19.4	0.5	
Other current liabilities	12.0	7.6	6.7	-0.8	
Subtotal	461.2	331.5	297.1	-34.5	
Liabilities directly associated with assets held for sale	-	-	0.4	0.4	
Total current liabilities	461.2	331.5	297.5	-34.1	
Non-current liabilities					
Bonds and borrowings	263.3	221.0	201.0	-20.0	
Other financial liabilities	14.2	7.8	8.3	0.5	
Post employment benefit liabilities	8.9	7.3	11.6	4.3	
Provisions	3.7	2.8	2.7	-0.1	
Deferred tax liabilities	39.8	30.7	88.4	57.7	Daiichi Sankyo +51.7 Bn (Tax effects from gain on merger of subsidiary +81.5 Bn)
Other non-current liabilities	55.3	55.0	65.7	10.7	
Total non-current liabilities	385.3	324.6	377.7	53.1	
Total liabilities	846.5	656.2	675.2	19.1	
Equity					
Equity attributable to owners of the Company					
Share capital	50.0	50.0	50.0	0.0	
Capital surplus	105.3	105.2	105.3	0.1	
Treasury shares	-14.4	-14.4	-14.2	0.2	
Other components of equity	121.8	112.3	169.0	56.8	Exchange differences on translation of foreign operations +26.0 Bn, Financial assets measured at fair value through other comprehensive income +25.6 Bn
Retained earnings	717.3	739.5	994.0	254.4	Profit for the year(owners of the Company) +322.1 Bn, Dividends -42.2 Bn
Total equity attributable to owners of the Company	979.9	992.6	1,304.1	311.5	
Non-controlling interests					
Non-controlling interests	27.6	5.4	3.0	-2.4	
Total equity	1,007.5	997.9	1,307.0	309.1	
Total liabilities and equity	1,854.0	1,654.1	1,982.3	328.2	

9. Consolidated Statement of Cash Flows

(Billions of yen)

	FY2013 Results	FY2014 Results	YoY	Notes
Cash flows from operating activities				
Profit before tax from continuing operations	113.0	79.9	-33.0	
Depreciation and amortization	38.4	42.0	3.7	
(Increase) decrease in receivables and payables	9.8	2.7	-7.1	
Other, net	-12.8	30.8	43.6	FY2014: Impairment loss of rights related to Zelboraf (+35.0 Bn)
Income taxes paid	-48.2	-21.9	26.3	
Cash flows from operating activities of discontinued operations	-62.8	9.2	72.1	
Net cash flows from operating activities	37.3	142.8	105.5	
Cash flows from investing activities				
Net (increase) decrease in time deposits and securities	-161.5	140.2	301.7	
(Acquisition of) proceeds from sales of fixed assets	-29.2	-93.4	-64.3	
(Acquisition of) subsidiary	—	-33.5	-33.5	FY2014: Acquisition of Ambit Biosciences Corp.
Other, net	1.7	2.1	0.4	
Cash flows from investing activities of discontinued operations	27.5	-36.7	-64.3	
Net cash flows from investing activities	-161.4	-21.3	140.1	
Cash flows from financing activities				
Proceeds from bonds and borrowings	140.9	0.0	-140.9	
Repayments of bonds and borrowings	-20.3	-90.0	-69.7	
Dividends paid	-42.2	-42.3	-0.0	
Other, net	-0.9	-0.9	-0.0	
Cash flows from financing activities of discontinued operations	22.9	1.0	-21.9	
Net cash flows from financing activities	100.3	-132.2	-232.5	
Net increase (decrease) in cash and cash equivalents	-23.7	-10.7	13.0	
Cash and cash equivalents at the beginning of the period	191.1	183.1	-8.1	
Effect of exchange rate changes on cash and cash equivalents	15.7	17.0	1.3	
Cash and cash equivalents at the end of the period	183.1	189.4	6.3	

10. Summary of Product Outlines

Brand Name	Generic Name	Therapeutic Category	Launched	Origin	Marketing Alliance
Japan Company (domestic sales)					
Olmotec	olmesartan	antihypertensive	2004	Daiichi Sankyo	
Nexium	esomeprazole	proton pump inhibitor	2011	AstraZeneca	AstraZeneca
Loxonin			1986	Daiichi Sankyo	
Loxonin Poultice			2006	Lead Chemical	
Loxonin Tape	loxoprofen	analgesic and anti-inflammatory	2008	Lead Chemical	
Loxonin Gel			2010	Daiichi Sankyo	
Memory	memantine	treatment for Alzheimer's Disease	2011	Merz	
Cravit	levofloxacin	antibacterial	1993	Daiichi Sankyo	
Rezaltas	olmesartan / azelnidipine	antihypertensive	2010	Daiichi Sankyo	
Artist	carvedilol	antihypertensive	1993	Roche	
Mevalotin	pravastatin	antihyperlipidemic	1989	Daiichi Sankyo	
Omnipaque	iohexol	contrast medium	1987	GE Healthcare	
Pralia	denosumab	anti-RANKL antibody	2013	Amgen	
Ranmark	denosumab	anti-RANKL antibody	2012	Amgen	
Inavir	laninamivir	anti-influenza	2010	Daiichi Sankyo	
Urief	silodosin	treatment for dysuria	2006	Kissei	Kissei
Tenelia	teneligliptin	type 2 diabetes	2012	Mitsubishi Tanabe	Mitsubishi Tanabe
Lixiana	edoxaban	anticoagulant Direct Oral Factor Xa Inhibitor	2011	Daiichi Sankyo	
Efient	prasugrel	antiplatelet	2014	Daiichi Sankyo Ube Industries	
Daiichi Sankyo, Inc. (US)					
Olmecartan					
Benicar	olmesartan		2002		
Benicar HCT	olmesartan / hydrochlorothiazide	antihypertensive	2003	Daiichi Sankyo	
Azor	olmesartan / amlodipine		2007		
Tribenzor	olmesartan / amlodipine / hydrochlorothiazide		2010		
Welchol	colesevelam	antihyperlipidemic / type 2 diabetes	2000	Genzyme	
Effient	prasugrel	antiplatelet	2009	Daiichi Sankyo Ube Industries	Lilly
Savaysa	edoxaban	anticoagulant Direct Oral Factor Xa Inhibitor	2015	Daiichi Sankyo	
Luitpold Pharmaceuticals, Inc. (US)					
Venofer	iron sucrose injection	iron deficiency anemia	2000	Vifor Pharma	Fresenius
Injectafer	ferric carboxymaltose injection	iron deficiency anemia	2013	Vifor Pharma	
Daiichi Sankyo Europe GmbH					
Olmecartan					
Olmotec	olmesartan		2002		
Olmotec Plus	olmesartan / hydrochlorothiazide	antihypertensive	2005	Daiichi Sankyo	Menarini Pfizer Nycomed
Sevikar	olmesartan / amlodipine		2009		
Sevikar HCT	olmesartan / amlodipine / hydrochlorothiazide		2010		
Efient	prasugrel	antiplatelet	2009	Daiichi Sankyo Ube Industries	Lilly

◆ Launched/Approved

Generic Name	Class	Indication	Region	Status	Remarks
Edoxaban	Factor Xa inhibitor	Atrial Fibrillation (AF)	US	<u>Launched</u>	Approved Jan 2015, Feb 2015
			CH	<u>Launched</u>	Approved Mar 2015, May 2015
		Venous thromboembolism (VTE)	US	<u>Launched</u>	Approved Jan 2015, Feb 2015
			CH	<u>Launched</u>	Approved Mar 2015, May 2015
<p>The once daily oral anti coagulant (FXa inhibitor) discovered by Daiichi Sankyo. Edoxaban specifically, reversibly and directly inhibits the enzyme, Factor Xa, a clotting factor in the blood. Launched in Japan in July 2011 as the prevention of venous thromboembolism (VTE) in patients with total knee arthroplasty, total hip arthroplasty and hip fracture surgery. Additional indications for AF/VTE was approved in September 2014 and 60 mg tablet was launched in December 2014.</p>					

Underline: change after FY2014 3Q Financial Announcement in January 2015

◆ Filed

Generic Name	Class	Target indication	Region	Filing year/month
Edoxaban	Factor Xa inhibitor	Atrial Fibrillation (AF)	EU	Jan 2014 Apr 2015 CHMP recommendation for approval
			Others	BR (14/6*) TW (14/7), KR (14/9) * means June, 2014, ditto
		Venous thromboembolism (VTE)	EU	Jan 2014 Apr 2015 CHMP recommendation for approval
			Others	BR (14/6) TW (14/7), KR (14/9)
<p>The once daily oral anti coagulant (FXa inhibitor) discovered by Daiichi Sankyo. Edoxaban specifically, reversibly and directly inhibits the enzyme, Factor Xa, a clotting factor in the blood.</p>				
Levofloxacin	New quinolone	Infection disease	JP	Injection, additional indication Nov 2014
<p>Levofloxacin injection formation, which was launched in 2011for the treatment in respiratory tract infection. As LCM programme, the trials for urinary tract infection, surgical infection and gynecological infection are completed.</p>				

Underline: change after FY2015 3Q Financial Announcement in January 2015

◆ Under development (Phase1-3)

Generic Name / Project code number	Class	Target indication	Stage		Remarks
Prasugrel	Anti-platelet agent	Ischemic stroke	JP	P3	additional indication
		Sickle cell disease	US	P3	additional indication
Denosumab	Anti-RANKL antibody	Breast cancer adjuvant	JP	P3	additional indication
		Rheumatoid arthritis	JP	P3	additional indication
Tivantinib	MET inhibitor	Hepatocellular cancer	US/EU	P3	
Nimotuzumab	Anti-EGFR antibody	Gastric cancer	JP	P3	
		Esophageal cancer	JP	P1	
Vemurafenib	BRAF inhibitor	Melanoma adjuvant	US/EU	P3	additional indication
		Colorectal cancer	US/EU	P2	additional indication
Quizartinib	FLT3-ITD inhibitor	Acute myeloid leukemia	US/EU	P3	
PLX3397	FMS/KIT/FLT3-ITD inhibitor	<u>Tenosynovial Giant Cell Tumor (TGCT)</u>	<u>US/EU</u>	<u>P3</u>	including pigmented villonodular synovitis
		Acute myeloid leukemia	US	P2	
		Glioblastoma	US	P2	
		Melanoma	US	P2	
Mirogabalin	α2δ ligand	Fibromyalgia	US/EU	P3	
		Diabetic peripheral neuropathic pain	JP/Asia	P3	
		Postherpetic neuralgia	JP/Asia	P3	
Hydromorphone	Opioid mu-receptor agonist	Cancer pain	JP	P3	
CHS-0214	TNFα inhibitor	Rheumatoid Arthritis	JP	P3	etanercept biosimilar
CL-108	Opioid mu-receptor agonist combination	Acute pain	US	P3	co-develop with Charleston Laboratories
CS-3150	MR antagonist	Hypertension	JP	P2b	
		Diabetic nephropathy	JP	P2b	
DS-8500	GPR119 agonist	Diabetes	JP	P2	
Patritumab	Anti-HER3 antibody	Non small cell lung cancer	US/EU	P2	
		Non small cell lung cancer	JP	P1	
		Breast cancer	US	P2	
		Breast cancer	JP	P1	
		Head & Neck cancer	EU	P1	
SUN13837	Modulator of bFGF signaling system	Spinal cord injury	US/EU	P2	
GE-145	X-ray contrast media	Angiography	JP	P2	
Laninamivir	Neuraminidase inhibitor	Influenza	US/EU	P2	out-licensing with Biota
DS-1040	TAF1a inhibitor	Acute ischemic stroke	-	P1	
<u>DS-8312</u>	<u>Hypertriglyceridemia treatment</u>	<u>Hypertriglyceridemia</u>	-	<u>P1</u>	
U3-1565	Anti-HB-EGF antibody	Solid cancer	US/JP	P1	
DS-7423	PI3K/mTOR inhibitor	Solid cancer	US/JP	P1	

Underline: change after FY2014 3QFinancial Announcement in January 2015

◆ Under development (Phase1-3)

Generic Name / Project code number	Class	Target indication	Stage	Remarks
DS-3078	mTOR inhibitor	Solid cancer, lymphoma	US/EU P1	
DS-3032	MDM2 inhibitor	Solid cancer, lymphoma	US/JP P1	
PLX7486	FMS/TRK inhibitor	Solid cancer	US P1	
DS-8895	Anti-EPHA2 antibody	Solid cancer	JP P1	
DS-8273	Anti-DR5 antibody	Solid cancer	US P1	
PLX8394	BRAF inhibitor	Solid cancer, leukemia	US P1	
DS-6051	NTRK/ROS1 inhibitor	Solid cancer	US P1	
DS-5573	Anti-B7-H3 antibody	Solid cancer	JP P1	
<u>PLX9486</u>	<u>KIT inhibitor</u>	<u>Solid cancer</u>	<u>US</u> <u>P1</u>	
DS-1093	HIF-PH inhibitor	Anemia of chronic kidney disease	- P1	
DS-3801	GPR 38 agonist	Chronic obstipation	- P1	
DS-1971	Pain	Chronic pain	- P1	
DS-1501	Anti-Siglec-15 antibody	Osteoporosis	- P1	

Underline: change after FY2014 3Q Financial Announcement in January 2015

◆ Stage-up (major changes from the FY2014 3Q financial announcement in January 2015)

Generic Name / Project code number	Class	Target indication	Current stage	Remarks
Edoxaban	FXa inhibitor	Atrial Fibrillation (AF)	US	Launched
			CH	Approved Launched
		Venous thromboembolism (VTE)	US	Launched
			CH	Approved Launched
PLX3397	FMS/KIT/FLT3-ITD inhibitor	Tenosynovial Giant Cell Tumor	US/EU P3	including pigmented villonodular synovitis
DS-8312	Hypertriglyceridemia treatment	Hypertriglyceridemia	- P1	
PLX9486	KIT inhibitor	Solid cancer	US P1	

◆ Discontinue (major changes from the FY2014 3Q financial announcement in January 2015)

Generic Name / Project code number	Class	Target indication	Stage
PLX5622	FMS kinase inhibitor	Rheumatoid arthritis	- P1
< Reason for discontinuation > Plexikon decided to discontinue the development of PLX5622 after reviewing its study result.			

◆ Major R&D Pipeline Table

As of May, 2015

Therapeutic Area	Phase1	Phase2	Phase3	Application
Cardiovascular - Metabolics	<p>DS-1040 (Acute ischemic stroke / TAF1a inhibitor)</p> <p>DS-8312 (Hypertriglyceridemia)</p>	<p>CS-3150 (JP) (Hypertension / MR antagonist)</p> <p>CS-3150 (JP) (Diabetic nephropathy / MR antagonist)</p> <p>DS-8500 (JP) (Diabetes / GPR119 agonist)</p>	<p>Prasugrel (JP) (CS-747 / Ischemic stroke / anti-platelet agent)</p> <p>Prasugrel (US) (CS-747 / Sickle cell disease / anti-platelet agent)</p>	<p>Edoxaban (CH) (DU-176b / AF / oral factor Xa inhibitor)</p> <p>Edoxaban (EU/Others) (DU-176b / AF / oral factor Xa inhibitor)</p> <p>Edoxaban (CH) (DU-176b / VTE / oral factor Xa inhibitor)</p> <p>Edoxaban (EU/Others) (DU-176b / VTE / oral factor Xa inhibitor)</p>
Oncology	<p>U3-1565 (US/JP) (Anti-HB-EGF antibody)</p> <p>DS-7423 (US/JP) (PI3K/mTOR inhibitor)</p> <p>DS-3078 (US/EU) (mTOR inhibitor)</p> <p>DS-3032 (US/JP) (MDM2 inhibitor)</p> <p>PLX7486 (US) (FMS/TRK inhibitor)</p> <p>DS-8895 (JP) (Anti-EPHA2 antibody)</p> <p>DS-8273 (US) (Anti-DR5 antibody)</p> <p>PLX8394 (US) (BRAF inhibitor)</p> <p>DS-6051 (US) (NTRK/ROS1 inhibitor)</p> <p>DS-5573 (JP) (Anti-B7-H3 antibody)</p> <p>PLX9486 (US) (KIT inhibitor)</p>	<p>Patritumab (US/EU) (U3-1287 / Anti-HER3 antibody)</p> <p>Vemurafenib (US/EU) (PLX4032 / BRAF inhibitor)</p> <p>PLX3397 (US) (FMS/KIT/FLT3-ITD inhibitor)</p>	<p>Tivantinib (US/EU) (ARQ 197 / HCC / MET inhibitor)</p> <p>Denosumab (JP) (AMG 162 / Breast cancer adjuvant / Anti-RANKL antibody)</p> <p>Nimotuzumab (JP) (DE-766 / Gastric cancer / Anti-EGFR antibody)</p> <p>Vemurafenib (US/EU) (PLX4032 / Melanoma adjuvant / BRAF inhibitor)</p> <p>Quizartinib (US/EU) (AC220 / AML / FLT3-ITD inhibitor)</p> <p>PLX3397 (US/EU) (TGCT / FMS/KIT/FLT3-ITD inhibitor)</p>	
Others	<p>PLX5622 (Rheumatoid arthritis / FMS kinase inhibitor)</p> <p>DS-1093 (Anemia of chronic kidney disease/HIF-PH inhibitor)</p> <p>DS-3801 (Chronic obstipation/GPR38 agonist)</p> <p>DS-1971 (Chronic pain)</p> <p>DS-1501 (Anti-Siglec-15 antibody)</p>	<p>SUN13837 (US/EU) (Spinal cord injury / Modulator of bFGF signaling system)</p> <p>Laninamivir (US/EU) (CS-8958 / anti-influenza / Out licensing with Biota)</p> <p>Ioforninol (JP) (GE-145 / X-ray contrast media/Angiography)</p>	<p>Mirogabalin (US/EU) (DS-5565 / Fibromyalgia / α2δ ligand)</p> <p>Mirogabalin (JP/Asia) (DS-5565 / DPNP / α2δ ligand)</p> <p>Mirogabalin (JP/Asia) (DS-5565 / PHN / α2δ ligand)</p> <p>Denosumab (JP) (AMG 162 / Rheumatoid arthritis / Anti-RANKL antibody)</p> <p>Hydromorphone (JP) (DS-7113 / Cancer pain/ Opioid mu-receptor agonist)</p> <p>CHS-0214 (JP) (Etanercept BS/ Rheumatoid arthritis / TNFa inhibitor)</p> <p>CL-108 (US) (Acute pain / Opioid mu-receptor agonist combination)</p>	<p>Levofloxacin (JP) (DR-3355 / anti-infection / New quinolone)</p>

Cardiovascular-Metabolics

[Project after Phase 2]

Generic Name	Project code Number	Dosage Form	Class	Target Indication	Origin	Brand Name
Edoxaban	DU-176b	Oral	Factor Xa inhibitor	- Atrial fibrillation (AF) - Venous thromboembolism (VTE)	Daiichi Sankyo	Lixiana (JP) LIXIANA (EU, Planned) SAVAYSA (US)
<p><Summary> The once daily oral anti coagulant (FXa inhibitor). Edoxaban specifically, reversibly and directly inhibits the enzyme, Factor Xa, a clotting factor in the blood. Launched in Japan in July 2011 as the prevention of venous thromboembolism (VTE) in patients with total knee arthroplasty, total hip arthroplasty and hip fracture surgery.</p> <ul style="list-style-type: none"> • Hokusai-VTE (VTE) P3 study was presented at ESC 2013. • ENGAGE AF-TIMI 48 (AF) P3 study was presented at AHA 2013. • NDA for AF/VTE indication Approved (JP: Sep 2014, US: Jan 2015, Switzerland: Mar 2015), Filed (EU: Jan 2014) 						

Generic Name	Project code Number	Dosage Form	Class	Target Indication	Origin	Brand Name
Prasugrel	CS-747	Oral	Anti-platelet agent	- Ischemic stroke - Sickle cell disease	Daiichi Sankyo Ube Industries	Effient (US, Asia) Efient (JPN, EU)
<p><Summary> The oral antiplatelet agent. Prasugrel helps to keep blood platelets from clumping together and developing a blockage in an artery</p> <ul style="list-style-type: none"> • Co-development with Eli Lilly in the US and EU, development by Daiichi Sankyo in Japan. • [JP] Approved in Mar-2014 for the ischemic heart disease undergoing PCI and launched in May-2014. P3 studies for ischemic stroke are on-going. • [US] P3 study in pediatric sickle cell disease patients is on-going. 						

Generic Name	Project code Number	Dosage Form	Class	Target Indication	Origin	Brand Name
-	CS-3150	Oral	MR antagonist	- Hypertension - Diabetic nephropathy	Exelixis	TBD
<p><Summary> The agent inhibits aldosterone binding to Mineralocorticoid Receptor(MR) which stimulate the sodium absorption into kidney. This agent is expected antihypertensive and organ-protective effect.</p> <ul style="list-style-type: none"> • P2 study in essential hypertension in Japan was completed. • P2 study in diabetes with albuminuria in Japan was completed. On January 2015, Ph.2bs of HTN and DN started. 						

Generic Name	Project code Number	Dosage Form	Class	Target Indication	Origin	Brand Name
-	DS-8500	Oral	GPR119 agonist	- Diabetes	Daiichi Sankyo	TBD
<p><Summary> The agent agonistically acts on GPR119 which is expressed in small intestine and spleen cells, stimulates insulin secretion, and lowers blood sugar concentration.</p>						

Oncology

Generic Name	Project code Number	Dosage Form	Class	Target Indication	Origin	Brand Name
Tivantinib	ARQ 197	Oral	MET inhibitor	- Hepatocellular cancer	ArQule	TBD

<Summary>

The molecular-targeted agent to inhibit HGF(hepatocyte growth factor) receptor, Met which has multiple roles in intracellular signal transductions such as cancer cell proliferation, angiogenesis, invasion, and apoptosis induction.

- A P3 clinical study for HCC with MET high patients was started in Jan-2013.

Generic Name	Project code Number	Dosage Form	Class	Target Indication	Origin	Brand Name
Nimotuzumab	DE-766	Injection	Anti-EGFR antibody	- Gastric cancer - Esophageal cancer	InnoMab	TBD

<Summary>

The humanized monoclonal antibody to target Epidermal Growth Factor Receptor(EGFR). This antibody is expected to be a best in class EGFR, safety against the skin toxicity and the efficacy comparable to the other antibodies.

- P3 in Japan for Gastric cancer started in April 2013.

Generic Name	Project code Number	Dosage Form	Class	Target Indication	Origin	Brand Name
Quizartinib	AC220	Oral	FLT3-ITD inhibitor	- Acute myeloid leukemia	Daiichi Sankyo (Ambit)	TBD

<Summary>

Kinase inhibitor against a receptor-type tyrosine kinase, FLT3. Therapeutic effect for patients with acute myeloid leukemia harboring FLT-ITD3 mutation is expected.

Generic Name	Project code Number	Dosage Form	Class	Target Indication	Origin	Brand Name
Patritumab	U3-1287	Injection	Anti-HER3 antibody	- Non small cell lung cancer - Breast cancer - Head and neck cancer	Daiichi Sankyo (U3 Pharma)	TBD

<Summary>

The fully human monoclonal antibody to target HER3, one of the Epidermal Growth Factor Receptor (EGFR) family of proteins. HER 3 is overexpressed in many tumors of epithelial origin and HER2/HER3 dimers and EGFR/HER3 dimers are more potent to induce tumor cell proliferation than homodimers of HER2 or EGFR.

Generic Name	Project code Number	Dosage Form	Class	Target Indication	Origin	Brand Name
Vemurafenib	PLX4032	Oral	BRAF inhibitor	- Melanoma adjuvant - Colorectal cancer	Daiichi Sankyo (Plexikon)	Zelboraf

<Summary>

The molecular-targeted agent to inhibit BRAF V600E mutation. Launched since 2011 as personalized treatment for patients with unresectable or metastatic melanoma.

Generic Name	Project code Number	Dosage Form	Class	Target Indication	Origin	Brand Name
-	PLX3397	Oral	FMS/KIT/FLT3-ITD inhibitor	- Tenosynovial Giant Cell Tumor - Acute myeloid leukemia - Glioblastoma - Melanoma	Daiichi Sankyo (Plexikon)	TBD

<Summary>

The molecular-targeted agent to inhibit Fms, Kit and Flt3-ITD. This agent is expected to reduce tumor cell proliferation and expansion of metastases.

Others

Generic Name	Project code Number	Dosage Form	Class	Target Indication	Origin	Brand Name
Denosumab	AMG 162	Injection	Anti-RANKL antibody	- Breast cancer adjuvant - Rheumatoid arthritis	Amgen	SRE, GCTB: Ranmark(JP) Osteoporosis: Pralia(JP)

<Summary>

The fully human monoclonal antibody to target RANK Ligand, an essential mediator of osteoclast formation. Launched in Japan in April 2012 as treatment for bone complications stemming from multiple myeloma and bone metastases from solid tumors, in June 2013 as treatment for osteoporosis, and in May 2014 as treatment for giant cell tumor of bone.

- July, 2007 In-licensed from Amgen.
- P3 : Breast cancer adjuvant, Rheumatoid arthritis.

Generic Name	Project code Number	Dosage Form	Class	Target Indication	Origin	Brand Name
Levofloxacin	DR-3355	Injection	New quinolone	- Infection disease	Daiichi Sankyo	Cravit (JP) Levaquin (US) Tavanic (EU)

<Summary>

Levofloxacin injection formulation, which was launched in 2011 for the treatment in respiratory tract infection. As LCM programme, the trials for urinary tract infection, surgical infection and gynecological infection are completed.

- A P3 comparative study for urinary tract infection and 4 open studies completed. sNDA submitted in Nov 2014.

Generic Name	Project code Number	Dosage Form	Class	Target Indication	Origin	Brand Name
-	CHS-0214	Injection	TNF α inhibitor	- Rheumatoid arthritis	Coherus	TBD

<Summary>

Biosimilar product for etanercept

- Phase 3 study for patients with rheumatoid arthritis in Japan was started in August 2014.

Generic Name	Project code Number	Dosage Form	Class	Target Indication	Origin	Brand Name
-	CL-108	Oral	opioid mu-receptor regulator	- Acute pain	Charleston Laboratories	TBD

<Summary>

Combination product of immediate-release promethazine, hydrocodone and acetaminophen. Reduction of Opioid-Induced Nausea and Vomiting is expected.

- Under phase 3 development in collaboration with Charleston Laboratories

Generic Name	Project code Number	Dosage Form	Class	Target Indication	Origin	Brand Name
Mirogabalin	DS-5565	Oral	$\alpha 2\delta$ ligand	- Fibromyalgia - Diabetic peripheral neuropathic pain - Postherpetic neuralgia	Daiichi Sankyo	TBD

<Summary>

The pain therapy agent to reduce the neurotransmitter release from nerve terminals. This agent is expected to show the good balanced efficacy and safety profile.

- Ph2 studies for diabetic peripheral neuropathic pain were completed.
- Ph3 studies for diabetic peripheral neuropathic pain and postherpetic neuralgia are in execution .
- Ph3 studies for fibromyalgia are in execution .

Generic Name	Project code Number	Dosage Form	Class	Target Indication	Origin	Brand Name
Hydromorphone	DS-7113	Oral/ Injection	opioid mu-receptor regulator	- Cancer pain	-	TBD

<Summary>

The opiate, narcotic analgesic that has been available outside of Japan for over 80 years and recommended in WHO guideline as a standard analgesia for cancer pain. It is designated as unapproved drug by "Study Group on Unapproved and Off-label Drugs of High Medical Need."

- Ph2 and Ph3 studies for immediate-release tablet, Ph3 studies for extended-release tablet, and Ph2/3 studies for injection formulation are ongoing.

Generic Name	Project code Number	Dosage Form	Class	- Target Indication	Origin	Brand Name
-	SUN13837	Injection	Modulator of bFGF signaling system	- Spinal cord injury	Daiichi Sankyo (Asubio Pharma)	TBD
<p><Summary> By accelerating self-regeneration capabilities (nerve cell protection, nerve axon elongation) with bFGF like cell differentiation actions, the perceptual and motor-functional dysfunctions caused by cord injuries are to be improved</p>						
Generic Name	Project code Number	Dosage Form	Class	Target Indication	Origin	Brand Name
Ioforninol	GE-145	Injection	X-ray contrast media	- Angiography	GE Healthcare	TBD
<p><Summary> Dimeric X-ray contrast medium, which is expected to reduce heat sensation and pain.</p>						

1. Summary of Consolidated Statement of Profit or Loss (IFRS FY2013)

JPY Bn	Q1		Q2		Q3		Q4		FY2013			
	to revenue	Results	to revenue	Results	to revenue	Results	to revenue	Results	to revenue	Results	YoY	YoY
Revenue	100%	252.6	100%	264.1	100%	288.8	100%	312.7	100%	1,118.2	123.6	12.4%
Cost of sales	35%	87.6	33%	86.5	35%	102.4	40%	125.8	36%	402.3	63.8	18.8%
Gross Profit	65%	165.0	67%	177.7	65%	186.3	60%	186.9	64%	716.0	59.8	9.1%
SG&A expenses	40%	101.7	35%	93.4	32%	91.5	40%	126.5	37%	413.2	40.2	10.8%
(General expenses) ^{*1}	35%	88.1	34%	90.7	34%	98.6	38%	120.0	36%	397.3		
(Asset related expenses) ^{*2}	1%	2.9	1%	2.8	-3%	-8.7	2%	6.0	0%	3.0		
(Loss on restructuring)	4%	10.8	0%	-0.1	1%	1.5	0%	0.6	1%	12.9		
R&D expenses	19%	48.1	18%	46.7	15%	42.2	17%	54.1	17%	191.2	6.8	3.7%
Operating Profit	6%	15.2	14%	37.5	18%	52.6	2%	6.3	10%	111.6	12.8	13.0%
Financial income/expenses		2.5		-10.9		-2.8		0.9		16.6	-7.9	
Share of profit or loss of investments accounted for using the equity method		-0.1		-0.2		-0.0		-1.1		26.9	16.6	
Profit before tax	7%	17.5	10%	26.3	17%	49.8	2%	6.1	9%	99.8	3.9	4.1%
Income taxes		2.1		10.1		14.5		19.7		46.4	16.5	
Profit for the year	6%	15.4							5%	53.4	16.5	
Profit attributable to owners of the Company	6%	15.0	7%	18.5	13%	38.0	-3%	-10.5	5%	60.9	-3.1	-4.8%
Currency Rate		Q1		Q2 YTD		Q3 YTD		Q4 YTD		FY2013		
		Results		Results		Results		Results		Results	YoY	
USD/JPY (average)		98.76		98.86		99.39		100.24		100.24	+17.13	
EUR/JPY (average)		128.96		130.01		132.24		134.38		134.38	+27.23	
INR/JPY (average)		1.71		1.74		1.69		1.68		1.68	+0.18	

^{*1} Incl. A&P expenses, Personnel expenses and other SG&A expenses

^{*2} Incl. Depreciation, Profit or Loss from sales of non-current assets, Impairment loss etc.

2. Segment Information

Daiichi Sankyo Group	Q1		Q2		Q3		Q4		FY2013			
	to revenue	Results	to revenue	Results	to revenue	Results	to revenue	Results	to revenue	Results	YoY	YoY
External revenue		210.0		218.3		244.3		225.0		897.7		
Intersegment revenue		0.4		0.4		0.4		0.3		1.4		
Revenue	100%	210.4	100%	218.7	100%	244.7	100%	225.3	100%	899.1	86.2	11%
Cost of sales	31%	65.9	29%	63.4	32%	77.2	34%	76.5	31%	282.9	26.9	10%
Gross Profit	69%	144.5	71%	155.3	68%	167.5	66%	148.8	69%	616.2	59.3	11%
SG&A expenses	40%	84.1	35%	75.6	30%	73.2	40%	89.8	36%	322.7	24.6	8%
(General expenses) ^{*1}	34%	72.1	34%	74.4	33%	81.4	38%	86.7	35%	314.6		
(Asset related expenses) ^{*2}	1%	1.2	1%	1.2	-4%	-9.7	1%	2.5	-1%	-4.8		
(Loss on restructuring)	5%	10.8	0%	-0.1	1%	2.0	0%	0.1	1%	12.9		
R&D expenses	22%	45.8	20%	44.2	16%	40.3	22%	50.3	20%	180.7	3.5	2%
Operating Profit	7%	14.6	16%	35.5	22%	54.0	4%	8.7	13%	112.9	31.1	38%
Financial income and expense		1.4		-1.2		3.1		-2.7		0.6	-0.1	
Share of profit or loss of investments accounted for using the equity method		-0.1		-0.1		0.1		-0.5		-0.6	-0.7	
Profit before tax	8%	15.9	16%	34.3	23%	57.2	2%	5.5	13%	112.9	30.4	37%
Income taxes		2.3		13.5		15.7		15.6		47.1	26.2	
Profit for the year		13.6		20.7		41.6		-10.1		65.8	4.2	
Profit attributable to owners of the Company	7%	13.9	10%	21.3	17%	41.9	-4%	-8.3	8%	68.8	7.4	12%
Ranbaxy Group												
External revenue		42.6		45.8		44.4		87.7		220.6		
Intersegment revenue		0.3		0.3		0.5		1.0		2.1		
Revenue	100%	42.9	100%	46.1	100%	44.9	100%	88.7	100%	222.7	37.5	20%
Cost of sales	52%	22.3	52%	23.8	57%	25.8	57%	50.5	55%	122.4	37.5	44%
Gross Profit	48%	20.6	48%	22.3	43%	19.1	43%	38.2	45%	100.3	0.0	0%
SG&A expenses	39%	16.9	41%	19.1	39%	17.4	41%	36.3	40%	89.8	17.5	24%
R&D expenses	6%	2.6	6%	2.6	5%	2.1	5%	4.2	5%	11.5	3.5	43%
Operating Profit	3%	1.2	1%	0.6	-1%	-0.4	-3%	-2.3	0%	-1.0	-20.9	-105%
Financial income and expense		1.0		-9.9		-6.0		0.7		-14.2	-10.9	
Share of profit or loss of investments accounted for using the equity method		-0.0		-0.1		-0.1		-0.1		-0.2	0.0	
Profit before tax	5%	2.1	-20%	-9.4	-14%	-6.5	-2%	-1.7	-7%	-15.4	-31.8	-194%
Income taxes		-0.5		-3.2		-0.9		3.8		-0.8	-7.2	
Profit for the year		2.6		-6.2		-5.6		-5.4		-14.6	-24.6	
Profit attributable to owners of the Company	6%	2.6	-14%	-6.2	-12%	-5.6	-6%	-5.3	-7%	-14.6	-24.4	-248%
Inter-segment Transactions												
Revenue		-0.7		-0.8		-0.9		-1.3		-3.6	-0.1	
Cost of sales		-0.6		-0.7		-0.5		-1.1		-3.0	-0.5	
Gross Profit		-0.1		-0.0		-0.3		-0.1		-0.6	0.5	
SG&A expenses		0.8		-1.3		0.8		0.4		0.7	-2.0	
R&D expenses		-0.3		-0.1		-0.1		-0.4		-0.9	-0.2	
Operating Profit		-0.6		1.4		-1.0		-0.1		-0.4	2.6	
Financial income and expense		0.1		0.1		0.1		2.9		3.2	3.1	
Share of profit or loss of investments accounted for using the equity method		-0.0		-0.0		-0.0		-0.5		-0.6	-0.4	
Profit before tax		-0.6		1.5		-1.0		2.3		2.2	5.3	
Income taxes		0.3		-0.3		-0.3		0.4		0.1	-2.6	
Profit for the year		-0.9		1.7		-0.7		1.9		2.1	7.9	
Profit attributable to owners of the Company		-1.5		3.4		1.6		3.1		6.7	13.9	

*1 Incl. A&P expenses, Personnel expenses and other SG&A expenses

*2 Incl. Depreciation, Profit or Loss from sales of non-current assets, Impairment loss etc.

3. Revenue by Business Units (FY2013)

	FY2013 Plan(Jan)	Q1			Q2			Q3			Q4			FY2013*					
		Results	YoY	to plan	Results	YoY	to plan	Results	YoY	to plan	Results	YoY	YoY	to plan	Results	YoY	YoY	to plan	
JPY Bn																			
Consolidated Revenue	1,110.0	252.5	+4.1%	23%	263.9	+9.3%	24%	290.7	+11.2%	26%	311.2	+23.4%	28%	1,118.2	123.6	+12.4%	101%		
Japan Company (domestic sales)+Vaccine business	485.0	108.5	+8.7%	-	117.1	+5.5%	-	138.6	+11.1%	-	122.3	+5.7%	-	486.5	30.5	+6.7%	-		
Olmetec	83.0	16.6	-8.9%	20%	20.9	+8.4%	25%	22.9	+9.4%	28%	18.7	-5.9%	23%	79.1	0.8	+1.0%	95%		
Rezaltas	21.0	4.3	+9.6%	21%	4.6	+12.2%	22%	5.2	+13.5%	25%	4.3	+1.0%	21%	18.5	1.5	+9.1%	88%		
Calblock	9.0	2.4	-11.1%	27%	2.4	-14.5%	26%	2.3	-18.2%	26%	1.8	-30.2%	20%	8.9	-2.0	-18.3%	99%		
Loxonin	61.0	14.9	+5.8%	25%	15.7	+0.6%	26%	16.2	-0.1%	27%	12.5	-9.1%	20%	59.3	-0.3	-0.6%	97%		
Cravit	35.0	7.6	-5.4%	22%	8.1	-4.0%	23%	10.2	-4.4%	29%	7.6	-13.1%	22%	33.5	-2.4	-6.7%	96%		
Nexium	52.0	10.9	+562.1%	21%	13.1	+375.9%	25%	16.2	+95.3%	31%	14.0	+58.1%	27%	54.2	32.7	+151.5%	104%		
Memary	34.0	6.6	+28.7%	19%	7.8	+38.2%	23%	9.5	+43.9%	28%	9.5	+46.5%	28%	33.3	9.5	+40.0%	98%		
Mevalotin	22.0	5.2	-20.5%	24%	5.9	-12.5%	27%	5.9	-10.0%	27%	4.5	-24.9%	20%	21.5	-4.3	-16.8%	98%		
Artist	22.0	5.4	-3.4%	25%	5.7	+0.6%	26%	6.0	+3.6%	28%	5.3	-0.9%	24%	22.4	0.0	+0.0%	102%		
Omnipaque	19.0	4.7	-4.0%	25%	5.2	-0.7%	28%	5.6	+4.3%	29%	4.1	-10.7%	22%	19.7	-0.5	-2.5%	104%		
Urief	12.0	2.7	+0.1%	22%	2.9	+4.2%	24%	3.2	+9.4%	27%	2.6	-2.1%	22%	11.4	0.3	+3.1%	95%		
Inavir	10.0	0.3	-38.8%	3%	0.0	-90.6%	0%	1.8	-15.2%	18%	11.4	+33.3%	114%	13.4	2.3	+20.8%	135%		
Ranmark	7.0	1.6	+162.8%	22%	1.9	+68.0%	27%	2.4	+76.8%	34%	2.3	+64.2%	32%	8.1	3.6	+82.2%	115%		
Pralia	not disclosed	0.4	-	-	0.6	-	-	0.8	-	-	1.5	-	-	3.2	3.2	-	-		
Daiichi Sankyo Espha products	not disclosed	2.9	+3.6%	-	3.0	+13.2%	-	3.8	+27.3%	-	2.7	+4.5%	-	12.5	1.4	+12.5%	-		
Vaccines business	not disclosed	9.3	+64.2%	-	8.3	-26.3%	-	13.9	-8.6%	-	6.1	-13.8%	-	37.5	-1.6	-4.2%	-		
Daiichi Sankyo Healthcare (OTC)	48.0	9.8	-4.6%	20%	13.1	+2.5%	27%	14.1	-2.8%	29%	11.0	+16.1%	23%	48.1	1.0	+2.1%	100%		
Daiichi Sankyo, Inc. (US)	163.0	46.6	+29.7%	29%	39.9	+22.2%	25%	44.6	+19.3%	27%	40.7	+11.9%	25%	171.8	29.4	+20.7%	105%		
Olmesartan	103.0	30.7	+28.4%	30%	26.1	+20.0%	25%	28.7	+11.8%	28%	26.8	+13.6%	26%	112.3	17.4	+18.3%	109%		
Benicar/Benicar HCT	79.0	23.8	+26.1%	30%	20.2	+20.6%	26%	21.6	+7.0%	27%	20.3	+16.3%	26%	85.9	12.6	+17.2%	109%		
Azor	15.0	4.6	+31.6%	31%	3.8	+9.3%	25%	4.4	+15.6%	29%	4.6	+13.6%	31%	17.4	2.6	+17.4%	116%		
Tribenzor	8.0	2.3	+49.3%	29%	2.1	+39.1%	26%	2.7	+62.6%	33%	1.9	-8.5%	24%	9.0	2.2	+32.3%	113%		
Welchol	43.0	11.4	+37.4%	26%	9.6	+33.8%	22%	11.7	+39.8%	27%	9.6	+3.2%	22%	42.3	9.1	+27.6%	98%		
Effient (alliance revenue)	not disclosed	4.0	+65.0%	-	3.6	+55.1%	-	3.8	+38.8%	-	4.0	+32.6%	-	15.4	4.9	+46.7%	-		
Luitpold Pharmaceuticals, Inc. (US)	40.0	8.1	-28.7%	20%	10.2	+32.0%	25%	9.6	-15.6%	24%	11.8	+43.6%	30%	39.6	1.0	+2.6%	99%		
Venofer	26.0	4.9	-27.7%	19%	6.8	+76.5%	26%	6.4	-23.0%	25%	6.8	+45.7%	26%	24.9	1.3	+5.4%	96%		
Injectafer	not disclosed	-	-	-	0.2	-	-	0.3	-	-	0.8	-	-	1.3	1.3	-	-		
Daiichi Sankyo Europe GmbH	78.0	19.0	+36.8%	24%	21.4	+41.8%	27%	23.3	+37.6%	30%	20.2	+9.3%	26%	83.9	19.5	+30.3%	108%		
Olmesartan	60.0	14.4	+45.0%	24%	16.8	+48.0%	28%	18.7	+44.7%	31%	15.8	+14.0%	26%	65.6	17.6	+36.7%	109%		
Olmetec/Olmetec Plus	41.0	9.8	+52.4%	24%	11.6	+42.6%	28%	12.7	+47.8%	31%	10.5	+10.7%	26%	44.5	11.9	+36.7%	109%		
Sevikar	12.0	3.0	+19.5%	25%	3.1	+32.6%	26%	4.0	+30.2%	33%	3.4	+19.5%	29%	13.5	2.7	+25.3%	112%		
Sevikar HCT	6.0	1.6	+62.2%	26%	2.1	+136.2%	35%	2.0	+58.8%	34%	1.9	+23.6%	32%	7.6	2.9	+62.9%	127%		
Efient (alliance revenue)	not disclosed	1.2	+30.3%	-	1.1	+23.1%	-	1.2	+32.5%	-	1.2	+1.2%	-	4.7	-	+20.5%	-		
Asia, South and Central America (ASCA)	46.0	12.7	+49.0%	-	14.1	+50.8%	-	15.0	+55.8%	-	16.9	-9.5%	-	58.8	12.6	+27.3%	-		
Daiichi Sankyo China	not disclosed	4.7	+77.3%	-	4.9	+62.6%	-	5.3	+71.4%	-	6.3	-18.1%	-	21.2	4.8	+29.2%	-		
Daiichi Sankyo Taiwan	not disclosed	1.1	+40.0%	-	1.1	+37.5%	-	1.1	+37.6%	-	1.2	+28.4%	-	4.5	1.2	+35.6%	-		
Daiichi Sankyo Korea	not disclosed	1.8	+44.6%	-	2.2	+79.1%	-	2.7	+102.1%	-	2.4	+55.3%	-	9.1	3.7	+69.8%	-		
Daiichi Sankyo (Thailand)	not disclosed	0.4	+46.7%	-	0.4	+36.5%	-	0.8	+107.1%	-	0.9	+112.9%	-	2.5	1.1	+81.4%	-		
Daiichi Sankyo Brasil Farmacêutica	not disclosed	1.7	+40.8%	-	2.0	+72.5%	-	2.0	+100.5%	-	1.8	-44.5%	-	7.5	0.9	+13.8%	-		
Daiichi Sankyo Venezuela	not disclosed	1.3	+48.4%	-	1.8	+22.7%	-	1.5	-1.5%	-	2.4	-18.4%	-	6.9	0.2	+2.7%	-		
Ranbaxy Group**	224.0	42.3	-28.4%	-	45.7	-4.1%	-	44.5	+16.0%	-	88.1	+118.4%	-	220.6	35.1	+19.0%	-		
Others	26.0	5.5	-20.3%	-	2.4	-77.7%	-	1.1	-89.2%	-	0.1	-100.6%	-	9.0	-5.5	-73.4%	-		

* Of revenues included in "Others", revenues of "Export, royalty to US/EU region" is transferred to Japan Company, revenues of "Licensee business in ASCA region" is transferred to ASCA Company, revenues of "Vaccine business" is transferred to "Vaccine business" under Japan Company, respectively.

** Since Ranbaxy Group has changed their fiscal year-end from December to March, their FY2013 financial results is for 15 months. 6 months results from 2013 Oct. to 2014 March are shown in Q4 results.

[Reference] Revenue in Local Currency

	FY2013 Plan(Jan)	Q1			Q2			Q3			Q4			FY2013			
		Results	YoY	to plan	Results	YoY	to plan	Results	YoY	to plan	Results	YoY	to plan	Results	YoY	YoY	to plan
USD Mn																	
Daiichi Sankyo, Inc. (US)	1,682	472	+5.3%	28%	403.0	-3.0%	24%	444.0	-3.6%	26%	395.0	+1.7%	24%	1,714	1	+0.1%	102%
Olmesartan	1,063	311	+4.3%	29%	263	-4.7%	25%	286	-9.7%	27%	260	+3.8%	25%	1,120	-22	-1.9%	105%
Benicar/Benicar HCT	815	241	+2.4%	30%	204	-4.3%	25%	215	-13.7%	26%	197	+7.1%	24%	857	-25	-2.8%	105%
Azor	155	47	+6.9%	30%	38	-13.2%	25%	44	-6.6%	28%	45	+2.5%	29%	174	-5	-2.7%	112%
Tribenzor	83	23	+21.3%	28%	21	+10.5%	26%	26	+31.6%	32%	19	-19.6%	23%	90	8	+9.7%	109%
Welchol	444	115	+11.6%	26%	97	+6.2%	22%	116	+13.0%	26%	93	-7.8%	21%	422	23	+5.8%	95%
Effient (alliance revenue)	not disclosed	41	+34.0%	-	37	+23.2%	-	38	+12.0%	-	39	+18.7%	-	154	27	+21.6%	-
USD Mn																	
Luitpold Pharmaceuticals, Inc. (US)	413	82	-42.1%	20%	103.0	+4.4%	25%	95.0	-31.9%	23%	115.0	+36.2%	28%	395	-69	-14.9%	96%
Venofer	268	50	-41.2%	19%	68	+39.2%	26%	64	-38.0%	24%	66	+40.2%	25%	248	-36	-12.6%	93%
Injectafer	not disclosed	0	-	-	2	-	-	3	-	-	7	-	-	13	-	-	-
EUR Mn																	
Daiichi Sankyo Europe GmbH	600	147	+9.2%	25%	163.0	+6.8%	27%	171.0	+6.0%	29%	143.0	-6.0%	24%	624	23	+3.9%	104%
Olmesartan	462	111	+15.7%	24%	128	+11.6%	28%	137	+11.4%	30%	112	-2.0%	24%	488	40	+9.0%	106%
Olmotec/Olmotec Plus	315	76	+21.6%	24%	89	+7.7%	28%	93	+13.9%	30%	74	-5.1%	23%	331	27	+9.0%	105%
Sevikar	92	23	-4.6%	25%	23	-0.5%	25%	29	+0.4%	32%	24	+4.7%	27%	100	-0	-0.1%	109%
Sevikar HCT	46	12	+29.4%	27%	16	+77.5%	35%	15	+21.6%	32%	13	+4.1%	29%	57	13	+29.9%	123%
Effient (alliance revenue)	not disclosed	9	+4.0%	-	8	-7.5%	-	9	+2.2%	-	8	-13.2%	-	35	-1	-3.9%	-
INR Bn																	
Ranbaxy Group*	135	25	-33.5%	-	26.0	-19.7%	-	28.0	+1.5%	-	53.0	+96.7%	-	131	30	+6.2%	-

* Since Ranbaxy Group has changed their fiscal year-end from December to March, their FY2013 financial results is for 15 months. 6 months results from 2013 Oct. to 2014 March are shown in Q4 results.

4. Revenue of Global Products (FY2013)

	FY2013 Plan(Jan)	Q1			Q2			Q3			Q4			FY2013			
		Results	YoY	to plan	Results	YoY	to plan	Results	YoY	to plan	Results	YoY	to plan	Results	YoY	YoY	to plan
JPY Bn																	
Olmesartan	289.0	71.4	+19.0%	25%	74.6	+22.7%	26%	81.9	+19.8%	28%	72.3	+3.7%	25%	300.2	41.3	+16.0%	104%
Olmotec (JPN)	83.0	16.6	-8.9%	20%	20.9	+8.4%	25%	22.9	+9.4%	28%	18.7	-5.9%	23%	79.1	0.8	+1.0%	95%
Rezaltas (JPN)	21.0	4.3	+9.6%	21%	4.6	+12.2%	22%	5.2	+13.5%	25%	4.3	+1.0%	21%	18.5	1.5	+9.1%	88%
Benicar/Benicar HCT (US)	79.0	23.8	+26.1%	30%	20.2	+20.6%	26%	21.6	+7.0%	27%	20.3	+16.3%	26%	85.9	12.6	+17.2%	109%
Azor (US)	15.0	4.6	+31.6%	31%	3.8	+9.3%	25%	4.4	+15.6%	29%	4.6	+13.6%	31%	17.4	2.6	+17.4%	116%
Tribenzor (US)	8.0	2.3	+49.3%	29%	2.1	+39.1%	26%	2.7	+62.6%	33%	1.9	-8.5%	24%	9.0	2.2	+32.3%	113%
Olmotec/Olmotec Plus (EU)	41.0	9.8	+52.4%	24%	11.6	+42.6%	28%	12.7	+47.8%	31%	10.5	+10.7%	26%	44.5	11.9	+36.7%	109%
Sevikar (EU)	12.0	3.0	+19.5%	25%	3.1	+32.6%	26%	4.0	+30.2%	33%	3.4	+19.5%	29%	13.5	2.7	+25.3%	112%
Sevikar HCT (EU)	6.0	1.6	+62.2%	26%	2.1	+136.2%	35%	2.0	+58.8%	34%	1.9	+23.6%	32%	7.6	2.9	+62.9%	127%
Other subsidiaries, export, etc	24.0	5.4	+35.4%	23%	6.2	+44.0%	26%	6.5	+49.9%	27%	6.7	-18.0%	28%	24.7	4.0	+19.2%	103%
Prasugrel	not disclosed	5.2	+55.6%	-	4.7	+46.3%	-	5.0	+37.2%	-	5.2	+24.0%	-	20.1	5.7	+39.6%	-
Effient alliance revenue (US)	not disclosed	4.0	+65.0%	-	3.6	+55.1%	-	3.8	+38.8%	-	4.0	+32.6%	-	15.4	4.9	+46.7%	-
Effient alliance revenue (EU)	not disclosed	1.2	+30.3%	-	1.1	+23.1%	-	1.2	+32.5%	-	1.2	+1.2%	-	4.7	0.8	+20.5%	-

1. Summary of Consolidated Income Statement (FY2012)

JPY Bn	Q1			Q2			Q3			Q4			FY2012			
	to sales	Results	YoY	to sales	Results	YoY	to sales	Results	YoY	to sales	Results	YoY	to sales	Results	YoY	YoY
Net sales	100%	242.6	+4.7%	100%	241.6	+7.7%	100%	261.5	+8.8%	100%	252.2	+4.1%	100%	997.9	59.2	+6.3%
Cost of sales	27%	66.7	+11.2%	32%	77.2	+11.9%	33%	86.4	+20.6%	33%	83.4	+22.6%	31%	313.7	45.0	+16.8%
Gross Profit	73%	176.0	+2.5%	68%	164.4	+5.8%	67%	175.1	+3.8%	67%	168.8	-3.1%	69%	684.2	14.1	+2.1%
SG&A expenses	59%	143.4	+11.8%	58%	139.8	+2.3%	53%	138.6	-0.3%	64%	161.8	-3.6%	58%	583.7	11.8	+2.1%
R&D expenses	17%	42.0	+2.5%	19%	45.2	+5.1%	17%	44.6	-0.3%	20%	51.2	-8.9%	18%	183.0	-2.0	-1.1%
A&P expenses	9%	22.7	+9.6%	9%	21.6	-8.9%	10%	25.3	+2.0%	11%	27.2	+2.7%	10%	96.8	1.1	+1.1%
Personnel expenses	14%	34.7	-0.4%	14%	34.2	-4.1%	13%	34.1	+1.2%	16%	40.7	+17.0%	14%	143.7	4.7	+3.4%
Other SG&A expenses	18%	44.0	+39.0%	16%	38.9	+13.1%	13%	34.6	-3.2%	17%	42.7	-15.2%	16%	160.2	8.0	+5.3%
Operating Income	13%	32.5	-25.2%	10%	24.6	+31.2%	14%	36.5	+22.9%	3%	7.0	+10.2%	10%	100.5	2.3	+2.4%
Non-operating income / expenses		8.3			-15.5			9.4			-3.5			-1.4	20.6	
Non-operating income		10.3			-5.3			8.1			4.5			17.6	7.6	
Non-operating expenses		2.0			10.2			-1.2			8.0			19.0	-13.0	
Ordinary Income	17%	40.8	-9.0%	4%	9.0	-58.0%	18%	45.8	+128.3%	1%	3.5	-	10%	99.1	22.9	+30.1%
Extraordinary income / losses		0.6			-5.2			-5.7			3.3			-7.1	35.2	
Extraordinary income		2.0			0.5			0.7			8.9			12.1	-2.7	
Extraordinary losses		1.5			5.7			6.4			5.7			19.2	-37.9	
Income before income taxes and minority interests	17%	41.4	-5.5%	2%	3.8	-79.1%	15%	40.2	-	3%	6.7	-	9%	92.1	58.2	+171.5%
Income taxes / minority interests		21.0			-0.1			13.0			-8.4			25.5	1.9	
Income taxes		16.8			3.0			10.2			-6.0			23.9	-15.9	
Minority interests		4.2			-3.1			2.8			-2.4			1.6	17.8	
Net Income	8%	20.4	-19.4%	2%	4.0	-66.3%	10%	27.1	-	6%	15.1	-	7%	66.6	56.2	+541.6%
Effective tax rate		41%			78%			25%			-90%			26%		
Overseas sales ratio results		54%			48%			44%			49%			49%		

2. Currency Rate (FY2012)

	Q1	Q2 YTD	Q3 YTD	Q4 YTD	FY2012	
	Results	Results	Results	Results	Results	YoY
USD/JPY (average)	80.21	79.42	80.01	83.11	83.11	+4.04
EUR/JPY (average)	102.91	100.64	102.18	107.15	107.15	-1.81
INR/JPY (average)	1.59	1.54	1.50	1.50	1.50	-0.23

3. Segment Information (FY2012)

Daiichi Sankyo Group	Q1			Q2			Q3			Q4			FY2012			
	to sales	Results	YoY	to sales	Results	YoY	to sales	Results	YoY	to sales	Results	YoY	to sales	Results	YoY	YoY
Sales to outside customers		183.5	-4.4%		193.9	+4.3%		223.1	+9.0%		211.9	+17.3%		812.4	49.2	+6.5%
Inter-segment sales		0.3			0.3			0.7			0.5			1.8	1.3	
Net sales	100%	183.8	-4.2%	100%	194.2	+4.4%	100%	223.8	+9.2%	100%	212.4	+17.6%	100%	814.2	50.6	+6.6%
Cost of sales	26%	47.9	+16.4%	29%	56.1	+16.2%	30%	67.3	+28.1%	29%	61.2	+35.5%	29%	232.5	45.3	+24.2%
Gross Profit	74%	135.9	-9.9%	71%	138.1	+0.3%	70%	156.5	+2.6%	71%	151.1	+11.6%	71%	581.7	5.2	+0.9%
SG&A expenses	63%	115.9	+4.2%	61%	117.8	-1.1%	54%	121.8	-0.4%	67%	142.3	+1.5%	61%	497.8	4.9	+1.0%
R&D expenses	22%	40.3	+3.1%	22%	43.2	+5.4%	19%	42.8	+0.2%	23%	49.3	-9.2%	22%	175.5	-1.4	-0.8%
Other expenses	41%	75.6	+4.8%	38%	74.6	-4.5%	35%	79.0	-0.8%	44%	93.0	+8.2%	40%	322.2	6.3	+2.0%
Operating Income	11%	20.1	-49.3%	10%	20.3	+8.9%	16%	34.7	+15.1%	4%	8.9	-	10%	84.0	0.3	+0.4%
Non-operating income		2.1			1.0			2.5			1.7			7.3	-0.8	
Non-operating expenses		1.0			1.6			1.2			1.8			5.6	0.8	
Ordinary Income	11%	21.1	-49.2%	10%	19.8	+4.2%	16%	36.1	+16.1%	4%	8.8	-	11%	85.7	-1.3	-1.4%
Extraordinary income		2.0			0.4			0.6			8.9			11.9	-2.4	
Extraordinary losses		1.3			5.7			6.3			2.5			15.8	0.1	
Income before income taxes and minority interests	12%	21.8	-46.2%	7%	14.5	-8.3%	14%	30.4	+2.8%	7%	15.2	-	10%	81.8	-3.8	-4.4%
Income taxes		8.1			4.4			6.9			-4.7			14.7	-36.6	
Minority interests		-0.1			-0.0			0.2			-0.0					
Net Income	7%	13.7	-40.1%	5%	10.2	-4.6%	10%	23.2	+110.3%	9%	19.9	-	8%	67.0	29.7	+79.4%

Ranbaxy Group	Q1			Q2			Q3			Q4			FY2012			
	to sales	Results	YoY	to sales	Results	YoY	to sales	Results	YoY	to sales	Results	YoY	to sales	Results	YoY	YoY
Sales to outside customers		59.1	+48.7%		47.6	+24.0%		38.3	+7.5%		40.3	-34.6%		185.4	9.9	+5.7%
Inter-segment sales		0.7			0.3			0.3			0.4			1.7	0.6	
Net sales	100%	59.8	+49.5%	100%	47.9	+24.1%	100%	38.6	+7.5%	100%	40.8	-34.3%	100%	187.1	10.5	+6.0%
Cost of sales	33%	19.5	+3.7%	45%	21.5	+3.7%	52%	20.1	+3.0%	56%	22.9	+0.6%	45%	83.9	2.2	+2.7%
Gross Profit	67%	40.3	+90.0%	55%	26.5	+47.7%	48%	18.5	+12.9%	44%	17.9	-54.5%	55%	103.2	8.4	+8.8%
SG&A expenses	44%	26.5	+66.2%	44%	20.9	+28.3%	41%	15.7	+0.5%	45%	18.4	-31.2%	44%	81.4	6.9	+9.3%
R&D expenses	3%	2.0	-12.3%	4%	2.1	-10.7%	5%	1.9	-17.0%	5%	2.1	-11.6%	4%	8.1	-1.2	-12.9%
Other expenses	41%	24.5	+79.4%	39%	18.7	+35.1%	36%	13.8	+3.6%	40%	16.3	-33.0%	39%	73.3	8.1	+12.5%
Operating Income	23%	13.8	+161.9%	12%	5.6	+238.2%	7%	2.9	+238.4%	-1%	-0.5	-103.9%	12%	21.8	1.4	+7.0%
Non-operating income		8.3			-6.2			5.7			2.8			10.4	7.3	
Non-operating expenses		0.8			8.6			-2.5			6.2			13.2	-13.9	
Ordinary Income	36%	21.2	+269.3%	-19%	-9.2	-317.5%	29%	11.0	-	-10%	-3.9	-	10%	19.1	22.6	-
Extraordinary income		0.0			0.0			0.0			0.0			0.1	-0.9	
Extraordinary losses		0.1			-0.0			0.0			3.2			3.4	-38.0	
Income before income taxes and minority interests	35%	21.1	+267.8%	-19%	-9.2	-321.2%	29%	11.0	-	-17%	-7.1	-	9%	15.9	59.6	-
Income taxes		6.1			-2.3			3.6			-1.1			6.3	16.5	
Minority interests		0.0			0.0			0.1			0.1			0.2	0.0	
Net Income	25%	15.0	+118.9%	-14%	-6.9	-297.1%	19%	7.4	-	-15%	-6.1	-	5%	9.4	43.1	-

Inter-segment Transactions

Net sales	-1.0	-0.6	-1.0	-0.9	-3.5
Cost of sales	-0.7	-0.4	-0.9	-0.7	-2.7
Gross Profit	-0.3	-0.2	-0.0	-0.2	-0.7
SG&A expenses	1.1	1.2	1.1	1.2	4.6
R&D expenses	-0.3	-0.1	-0.1	-0.1	-0.6
Other expenses	1.4	1.3	1.3	1.3	5.2
Operating Income	-1.4	-1.4	-1.1	-1.4	-5.3
Non-operating income	-0.0	-0.1	-0.1	0.0	-0.2
Non-operating expenses	0.1	0.0	0.0	0.0	0.2
Ordinary Income	-1.5	-1.5	-1.2	-1.4	-5.7
Extraordinary income	-	0.0	0.0	0.1	0.1
Extraordinary losses	0.0	-0.0	0.0	0.0	0.0
Income before income taxes and minority interests	-1.5	-1.5	-1.2	-1.4	-5.6
Income taxes	2.6	0.9	-0.3	-0.3	3.0
Minority interests	4.2	-3.1	2.6	-2.4	1.3
Net Income	-8.3	0.7	-3.5	1.3	-9.8

4. Sales by Business Units (FY2012)

	FY2012 Plan	Q1			Q2			Q3			Q4			FY2012			
		Results	YoY	to plan	Results	YoY	to plan	Results	YoY	to plan	Results	YoY	to plan	Results	YoY	to plan	
JPY Bn																	
Consolidated Net Sales	990.0	242.6	+4.7%	25%	241.6	+7.7%	24%	261.5	+8.8%	26%	252.2	+4.1%	26%	997.9	+6.3%	101%	
Japan Company (domestic sales)	440.0	98.2	-2.2%	22%	106.9	+6.3%	24%	124.7	+9.5%	28%	112.7	+18.8%	26%	442.5	+8.0%	101%	
Olmotec	76.0	18.2	-10.8%	24%	19.3	-5.5%	25%	20.9	-7.6%	28%	19.9	+14.3%	26%	78.3	-3.2%	103%	
Rezaltas	16.0	4.0	+38.6%	25%	4.1	+30.6%	26%	4.6	+16.9%	28%	4.3	+20.5%	27%	16.9	+25.7%	106%	
Calblock	10.0	2.7	-14.0%	27%	2.8	-12.9%	28%	2.8	-13.8%	28%	2.6	-5.5%	26%	10.9	-11.8%	109%	
Loxonin	60.0	14.1	-2.0%	24%	15.6	-0.4%	26%	16.2	-6.1%	27%	13.7	+0.0%	23%	59.6	-2.3%	99%	
Cravit	35.0	8.1	-4.2%	23%	8.4	+0.0%	24%	10.6	-2.0%	30%	8.8	+1.6%	25%	35.9	-1.2%	103%	
Nexium	22.0	1.7	-	8%	2.7	+7.1%	13%	8.3	+1254.8%	38%	8.9	+1113.9%	40%	21.6	+452.0%	98%	
Memary	26.0	5.1	+128.7%	20%	5.6	+247.5%	22%	6.6	+135.7%	25%	6.4	+103.0%	25%	23.8	+142.0%	92%	
Mevalotin	26.0	6.5	-25.7%	25%	6.8	-21.8%	26%	6.6	-25.6%	25%	6.0	-12.4%	23%	25.8	-21.9%	99%	
Artist	22.0	5.6	-8.9%	25%	5.6	-9.3%	26%	5.8	-10.9%	27%	5.3	-5.6%	24%	22.4	-8.8%	102%	
Omnipaque	20.0	4.9	-13.2%	25%	5.3	-15.9%	26%	5.4	-16.3%	27%	4.6	-11.1%	23%	20.2	-14.3%	101%	
Urief	11.0	2.7	+0.5%	24%	2.8	+0.1%	25%	3.0	-1.8%	27%	2.7	+5.7%	25%	11.1	+1.0%	101%	
Inavir	11.0	0.4	+10.3%	4%	0.1	-164.9%	1%	2.1	+22.9%	19%	8.6	-2.0%	78%	11.1	+3.8%	101%	
Ranmark	5.0	0.6	-	12%	1.1	-	22%	1.3	-	27%	1.4	-	27%	4.4	-	88%	
Vaccines	not disclosed	5.2	+13.9%	-	8.1	+52.5%	-	11.8	+72.2%	-	4.7	+3.5%	-	29.8	+40.2%	-	
Daiichi Sankyo Espha products	not disclosed	2.8	+16.2%	-	2.7	+12.7%	-	3.0	+2.4%	-	2.6	+20.7%	-	11.1	+12.2%	-	
Daiichi Sankyo Healthcare (OTC)	48.0	10.2	+5.0%	21%	12.8	+1.1%	27%	14.5	+6.1%	30%	9.5	-2.4%	20%	47.1	+2.7%	98%	
Daiichi Sankyo, Inc. (US)	139.0	35.9	+3.7%	26%	32.6	+10.0%	24%	37.4	+23.9%	27%	36.4	+11.6%	26%	142.3	+12.0%	102%	
Olmesartan	93.0	23.9	-3.8%	26%	21.7	+6.3%	23%	25.7	+24.9%	28%	23.6	+7.0%	25%	94.9	+7.9%	102%	
Benicar/Benicar HCT	73.0	18.9	-6.3%	26%	16.7	-0.6%	23%	20.2	+24.7%	28%	17.4	-3.8%	24%	73.2	+2.8%	100%	
Azor	14.0	3.5	-1.7%	25%	3.5	+40.0%	25%	3.8	+20.9%	27%	4.1	+42.7%	29%	14.8	+23.3%	106%	
Tribenzor	6.0	1.6	+30.8%	26%	1.5	+34.3%	25%	1.6	+37.1%	27%	2.1	+90.9%	35%	6.8	+47.8%	114%	
Welchol	31.0	8.3	+17.5%	27%	7.2	+10.5%	23%	8.3	+26.1%	27%	9.3	+39.4%	30%	33.1	+23.4%	107%	
Effient (alliance revenue)	not disclosed	2.4	+51.8%	-	2.3	+36.4%	-	2.7	+47.5%	-	3.0	+9.5%	-	10.5	+32.7%	-	
Luitpold Pharmaceuticals, Inc. (US)	38.0	11.3	-10.9%	30%	7.7	-17.4%	20%	11.3	-24.7%	30%	8.2	+7.7%	22%	38.6	-13.7%	102%	
Venofer	23.0	6.8	-7.4%	30%	3.8	-30.4%	17%	8.3	-8.5%	36%	4.7	+60.9%	20%	23.6	-4.9%	103%	
Daiichi Sankyo Europe GmbH	65.0	13.9	-17.6%	21%	15.1	-10.8%	23%	16.9	-2.6%	26%	18.5	-3.0%	29%	64.4	-8.3%	99%	
Olmesartan	48.0	9.9	-16.6%	21%	11.3	-6.6%	24%	12.9	+1.8%	27%	13.9	-3.1%	29%	48.0	-5.9%	100%	
Olmotec/Olmotec Plus	34.0	6.4	-26.5%	19%	8.1	-7.6%	24%	8.6	-6.9%	25%	9.4	-4.5%	28%	32.6	-11.1%	96%	
Sevikar	10.0	2.5	+4.5%	25%	2.3	-12.2%	23%	3.1	+17.4%	31%	2.9	-13.7%	29%	10.8	-2.0%	108%	
Sevikar HCT	4.0	1.0	+31.6%	24%	0.9	+25.7%	23%	1.3	+47.9%	32%	1.5	+43.3%	38%	4.7	+38.2%	117%	
Efient (alliance revenue)	not disclosed	0.9	+54.7%	-	0.9	+40.5%	-	0.9	+33.0%	-	1.2	+13.0%	-	3.9	+31.9%	-	
Asia, South and Central America (ASCA)¹	38.0	7.1	+9.8%	19%	8.1	+10.1%	21%	8.2	+18.4%	22%	17.1	+117.8%	45%	40.5	+41.6%	107%	
Daiichi Sankyo China ²	not disclosed	2.7	+0.9%	-	3.0	+16.0%	-	3.1	+50.9%	-	7.6	+214.7%	-	16.4	+68.8%	-	
Daiichi Sankyo Taiwan	not disclosed	0.8	-5.9%	-	0.8	-1.3%	-	0.8	+7.8%	-	0.9	+19.5%	-	3.3	+4.7%	-	
Daiichi Sankyo Korea	not disclosed	1.2	+2.1%	-	1.2	+5.5%	-	1.3	+16.8%	-	1.6	+40.0%	-	5.3	+15.8%	-	
Daiichi Sankyo (Thailand)	not disclosed	0.3	+3.7%	-	0.3	+2.7%	-	0.4	+14.5%	-	0.4	+38.7%	-	1.4	+15.6%	-	
Daiichi Sankyo Brasil Farmacêutica	not disclosed	1.2	+14.2%	-	1.2	-22.5%	-	1.0	-34.4%	-	3.2	+118.5%	-	6.6	+18.6%	-	
Daiichi Sankyo Venezuela	not disclosed	0.8	+87.0%	-	1.4	+49.5%	-	1.5	+37.1%	-	2.9	+75.9%	-	6.7	+60.7%	-	
Daiichi Sankyo Mexico S.A. de C.V	not disclosed	0.1	-	-	0.1	-	-	0.1	-	-	0.4	-	-	0.7	-	-	
Ranbaxy Laboratories Limited	179.0	59.1	+48.7%	33%	47.6	+24.0%	27%	38.3	+7.5%	21%	40.3	-34.6%	23%	185.4	+5.7%	104%	
Others	43.0	6.8	-38.0%	16%	10.7	+13.1%	25%	10.0	+32.8%	23%	9.5	+7.5%	22%	37.1	+0.5%	86%	
Levofloxacin export, royalty, etc	3.0	1.2	-60.1%	41%	1.0	-56.6%	34%	1.4	+19.3%	46%	0.6	-59.6%	21%	4.3	-47.8%	142%	
Plexxikon	not disclosed	0.1	-96.1%	-	1.4	-24.6%	-	1.0	+313.4%	-	0.5	-35.9%	-	3.1	-47.7%	-	

[Reference] Sales in Local Currency

	FY2012 Plan	Q1			Q2			Q3			Q4			FY2012		
		Results	YoY	to plan	Results	YoY	to plan	Results	YoY	to plan	Results	YoY	to plan	Results	YoY	to plan
USD Mn																
Daiichi Sankyo, Inc. (US)	1,711	448	+5.7%	26%	415	+8.7%	24%	461.0	+18.2%	27%	389.0	-5.6%	23%	1,713	+6.5%	100%
Olmesartan	1,144	298	-2.0%	26%	276	+4.9%	24%	317	+19.0%	28%	251	-9.9%	22%	1,142	+2.7%	100%
Benicar/Benicar HCT	898	235	-4.5%	26%	213	-1.8%	24%	249	+18.8%	28%	184	-19.6%	20%	881	-2.2%	98%
Azor	172	44	+0.2%	25%	44	+37.4%	26%	47	+15.5%	27%	44	+22.2%	25%	179	+17.3%	104%
Tribenzor	75	19	+33.3%	26%	19	+33.0%	26%	20	+30.9%	27%	23	+66.5%	31%	82	+40.6%	109%
Welchol	388	103	+19.7%	27%	92	+9.5%	24%	103	+20.3%	27%	101	+19.8%	26%	399	+17.4%	103%
Effient (alliance revenue)	not disclosed	30	+54.7%	-	30	+35.4%	-	34	+41.2%	-	33	-5.7%	-	127	+26.2%	-
USD Mn																
Luitpold Pharmaceuticals, Inc. (US)	468	141	-9.2%	30%	98	-18.5%	21%	140.0	-27.6%	30%	85.0	-11.8%	18%	465	-17.9%	99%
Venofer	288	85	-5.6%	30%	49	-31.0%	17%	103	-11.8%	36%	47	+29.8%	16%	284	-9.6%	99%
EUR Mn																
Daiichi Sankyo Europe GmbH	650	135	-6.0%	21%	153	-0.2%	24%	161.0	-2.6%	25%	152.0	-16.6%	23%	601	-6.7%	93%
Olmesartan	480	96	-4.8%	20%	115	+4.4%	24%	123	+2.0%	26%	114	-16.5%	24%	448	-4.3%	93%
Olmetec/Olmetec Plus	340	62	-16.2%	18%	82	+3.1%	24%	82	-6.8%	24%	78	-17.8%	23%	304	-9.6%	89%
Sevikar	100	24	+19.3%	25%	23	-1.1%	24%	29	+17.7%	29%	23	-26.4%	23%	100	-0.3%	100%
Sevikar HCT	40	9	+50.1%	24%	9	+41.0%	23%	12	+49.4%	30%	13	+27.1%	32%	44	+40.5%	109%
Effient (alliance revenue)	not disclosed	9	+76.5%	-	9	+57.9%	-	9	+33.5%	-	10	-1.0%	-	36	+34.1%	-
INR Bn																
Ranbaxy Laboratories Limited	105	37	+71.1%	35%	32	+53.1%	31%	27.0	+31.2%	26%	27.0	-28.9%	26%	124	+21.9%	117%

5. Sales of Global Products (FY2012)

	FY2012 Plan	Q1			Q2			Q3			Q4			FY2012		
		Results	YoY	to plan	Results	YoY	to plan	Results	YoY	to plan	Results	YoY	to plan	Results	YoY	to plan
JPY Bn																
Olmesartan	251.0	60.0	-5.3%	24%	60.8	+0.6%	24%	68.3	+6.4%	27%	69.7	+13.0%	28%	258.9	+3.7%	103%
Olmetec (JPN)	76.0	18.2	-10.8%	24%	19.3	-5.5%	25%	20.9	-7.6%	28%	19.9	+14.3%	26%	78.3	-3.2%	103%
Rezaltas (JPN)	16.0	4.0	+38.6%	25%	4.1	+30.6%	26%	4.6	+16.9%	28%	4.3	+20.5%	27%	16.9	+25.7%	106%
Benicar/Benicar HCT (US)	73.0	18.9	-6.3%	26%	16.7	-0.6%	23%	20.2	+24.7%	28%	17.4	-3.8%	24%	73.2	+2.8%	100%
Azor (US)	14.0	3.5	-1.7%	25%	3.5	+40.0%	25%	3.8	+20.9%	27%	4.1	+42.7%	29%	14.8	+23.3%	106%
Tribenzor (US)	6.0	1.6	+30.8%	26%	1.5	+34.3%	25%	1.6	+37.1%	27%	2.1	+90.9%	35%	6.8	+47.8%	114%
Olmetec/Olmetec Plus (EU)	34.0	6.4	-26.5%	19%	8.1	-7.6%	24%	8.6	-6.9%	25%	9.4	-4.5%	28%	32.6	-11.1%	96%
Sevikar (EU)	10.0	2.5	+4.5%	25%	2.3	-12.2%	23%	3.1	+17.4%	31%	2.9	-13.7%	29%	10.8	-2.0%	108%
Sevikar HCT (EU)	4.0	1.0	+31.6%	24%	0.9	+25.7%	23%	1.3	+47.9%	32%	1.5	+43.3%	38%	4.7	+38.2%	117%
Other subsidiaries, export, etc	18.0	4.0	+20.6%	22%	4.3	+0.1%	24%	4.3	-3.1%	24%	8.1	+82.8%	45%	20.7	+25.7%	115%
Prasugrel	not disclosed	3.3	+52.6%	-	3.2	+37.5%	-	3.7	+43.5%	-	4.2	+10.4%	-	14.4	+32.5%	-
Effient alliance revenue (US)	not disclosed	2.4	+51.8%	-	2.3	+36.4%	-	2.7	+47.5%	-	3.0	+9.5%	-	10.5	+32.7%	-
Effient alliance revenue (EU)	not disclosed	0.9	+54.7%	-	0.9	+40.5%	-	0.9	+33.0%	-	1.2	+13.0%	-	3.9	+31.9%	-

1. Summary of Consolidated Income Statement (FY2011)

JPY Bn	Q1			Q2			Q3			Q4			FY2011			
	to sales	Results	YoY	to sales	Results	YoY	to sales	Results	YoY	to sales	Results	YoY	to sales	Results	YoY	YoY
Net sales	100%	231.7	-9.7%	100%	224.4	-7.5%	100%	240.4	-3.5%	100%	242.3	+10.5%	100%	938.7	-28.7	-3.0%
Cost of sales	26%	59.9	-6.5%	31%	69.0	-7.4%	30%	71.7	-3.9%	28%	68.1	-0.8%	29%	268.6	-13.1	-4.6%
Gross Profit	74%	171.8	-10.7%	69%	155.4	-7.5%	70%	168.7	-3.4%	72%	174.2	+15.6%	71%	670.1	-15.6	-2.3%
SG&A expenses	55%	128.3	-2.3%	61%	136.7	-1.6%	58%	139.0	-3.5%	69%	167.9	+12.5%	61%	571.9	8.3	+1.5%
R&D expenses	18%	41.0	-5.9%	19%	43.0	-5.8%	19%	44.7	-15.6%	23%	56.3	+8.2%	20%	185.1	-9.3	-4.8%
A&P expenses	9%	20.7	-9.4%	11%	23.7	-4.6%	10%	24.8	-4.1%	11%	26.5	+1.4%	10%	95.7	-4.0	-4.0%
Personnel expenses	15%	34.9	+0.8%	16%	35.6	+0.5%	14%	33.7	+1.9%	14%	34.8	+0.0%	15%	139.0	1.1	+0.8%
Other SG&A expenses	14%	31.6	+4.6%	15%	34.4	+4.1%	15%	35.7	+11.3%	21%	50.4	+38.7%	16%	152.1	20.4	+15.5%
Operating Income	19%	43.5	-28.8%	8%	18.7	-35.6%	12%	29.7	-2.8%	3%	6.3	+318.5%	10%	98.2	-23.9	-19.6%
Non-operating income / expenses		1.4			2.8			-9.6			-16.5			-22.0	-31.6	
Non-operating income		4.5			4.8			-1.0			1.7			10.0	-13.2	
Non-operating expenses		3.1			2.0			8.6			18.3			32.0	18.4	
Ordinary Income	19%	44.8	-36.0%	10%	21.5	-4.6%	8%	20.1	-47.1%	-4%	-10.2	-	8%	76.2	-55.5	-42.2%
Extraordinary income / losses		-1.1			-3.2			-41.7			3.7			-42.3	-31.0	
Extraordinary income		1.2			0.7			0.2			12.7			14.8	2.0	
Extraordinary losses		2.3			4.0			41.9			9.0			57.1	32.9	
Income before income taxes and minority interests	19%	43.8	-33.8%	8%	18.3	-34.8%	-9%	-21.6	-	-3%	-6.5	-	4%	33.9	-86.5	-71.8%
Income taxes / minority interests		18.5			6.5			-2.1			0.7			23.5	-26.8	
Income taxes		16.4			6.3			15.2			1.8			39.8	-2.0	
Minority interests		2.1			0.2			-17.4			-1.2			-16.2	-24.7	
Net Income	11%	25.3	-23.5%	5%	11.7	-38.5%	-8%	-19.5	-	-3%	-7.2	-	1%	10.4	-59.7	-85.2%
Effective tax rate		37%			34%			-			-			117%		
Overseas sales ratio results		51%			48%			45%			56%			50%		

2. Currency Rate (FY2011)

	Q1	Q2 YTD	Q3 YTD	Q4 YTD	FY2011	
	Results	Results	Results	Results	Results	YoY
USD/JPY (average)	81.75	79.81	79.00	79.07	79.07	-6.65
EUR/JPY (average)	117.40	113.78	110.62	108.96	108.96	-4.17
INR/JPY (average)	1.83	1.83	1.79	1.73	1.73	-0.20

3. Segment Information (FY2011)

Daiichi Sankyo Group	Q1			Q2			Q3			Q4			FY2011			
	to sales	Results	YoY	to sales	Results	YoY	to sales	Results	YoY	to sales	Results	YoY	to sales	Results	YoY	YoY
Sales to outside customers		191.9	-4.8%		185.9	-6.5%		204.7	-4.2%		180.6	-0.4%		763.2	-32.2	-4.2%
Inter-segment sales		0.1			0.1			0.3			-0.0			0.5	0.4	
Net sales	100%	192.0	-4.8%	100%	186.0	-6.4%	100%	205.0	-4.1%	100%	180.6	-0.4%	100%	763.6	-31.8	-4.0%
Cost of sales	21%	41.1	-8.4%	26%	48.3	-11.2%	26%	52.5	-4.4%	25%	45.2	-5.0%	25%	187.1	-14.7	-7.3%
Gross Profit	79%	150.8	-3.8%	74%	137.7	-4.6%	74%	152.5	-3.9%	75%	135.4	+1.2%	76%	576.5	-17.2	-2.9%
SG&A expenses	58%	111.2	-2.0%	64%	119.1	-1.8%	60%	122.3	-4.2%	78%	140.2	+6.6%	65%	492.8	-1.0	-0.2%
R&D expenses	20%	39.1	-3.1%	22%	40.9	-5.9%	21%	42.7	-15.6%	30%	54.2	+9.4%	23%	177.0	-7.0	-3.8%
Other expenses	38%	72.1	-1.4%	42%	78.1	+0.5%	39%	79.6	+3.3%	48%	86.0	+5.0%	41%	315.9	6.0	+1.9%
Operating Income	21%	39.6	-8.5%	10%	18.7	-19.4%	15%	30.2	-2.9%	-3%	-4.8	-	11%	83.7	-16.1	-16.2%
Non-operating income		3.8			1.7			1.6			1.0			8.1	0.9	
Non-operating expenses		1.8			1.4			0.7			0.9			4.8	-2.3	
Ordinary Income	22%	41.6	-4.2%	10%	19.0	-17.8%	15%	31.1	-7.9%	-3%	-4.6	-	11%	87.0	-13.0	-13.0%
Extraordinary income		1.2			0.7			-0.0			12.5			14.3	4.1	
Extraordinary losses		2.3			3.8			1.5			8.1			15.7	-5.2	
Income before income taxes and minority interests	21%	40.4	+1.2%	9%	15.8	-38.9%	14%	29.5	-14.2%	0%	-0.2	-	11%	85.6	-3.7	-4.2%
Income taxes		17.8			5.9			18.9			8.6			51.2	20.7	
Minority interests		-0.2			-0.8			-0.4			-1.6					
Net Income	12%	22.9	+2.5%	6%	10.7	-41.9%	5%	11.0	-57.5%	-4%	-7.2	-	5%	37.4	-21.4	-36.4%
Ranbaxy Group																
Sales to outside customers		39.8	-27.5%		38.4	-12.0%		35.7	+0.6%		61.6	+62.3%		175.5	3.6	+2.0%
Inter-segment sales		0.2			0.2			0.2			0.4			1.1	-0.0	
Net sales	100%	40.0	-27.1%	100%	38.6	-11.7%	100%	35.9	+1.1%	100%	62.0	+59.5%	100%	176.6	3.5	+2.0%
Cost of sales	47%	18.8	-2.2%	54%	20.7	+3.3%	54%	19.5	-0.1%	37%	22.8	+8.2%	46%	81.7	2.0	+2.5%
Gross Profit	53%	21.2	-40.6%	46%	17.9	-24.5%	46%	16.4	+2.5%	63%	39.3	+120.0%	54%	94.8	1.5	+1.7%
SG&A expenses	40%	15.9	-2.6%	42%	16.3	-5.0%	43%	15.6	+1.2%	43%	26.7	+59.6%	42%	74.4	8.9	+13.5%
R&D expenses	6%	2.3	-30.8%	6%	2.4	-21.3%	6%	2.3	-19.1%	4%	2.3	-17.9%	5%	9.3	-2.7	-22.6%
Other expenses	34%	13.7	+4.5%	36%	13.9	-1.4%	37%	13.3	+5.8%	39%	24.3	+75.4%	37%	65.1	11.6	+21.6%
Operating Income	13%	5.3	-72.7%	4%	1.7	-74.9%	2%	0.9	+34.5%	20%	12.6	+998.6%	12%	20.4	-7.3	-26.4%
Non-operating income		1.7			3.1			-2.5			0.8			3.2	-13.0	
Non-operating expenses		1.3			0.5			7.9			17.4			27.0	23.1	
Ordinary Income	14%	5.8	-79.6%	11%	4.2	+353.5%	-26%	-9.5	-	-6%	-3.9	-	-2%	-3.4	-43.4	-
Extraordinary income		0.0			0.0			0.8			0.2			1.1	-4.1	
Extraordinary losses		0.0			0.1			0.0			41.2			41.4	33.1	
Income before income taxes and minority interests	14%	5.7	-79.2%	11%	4.2	-31.2%	-24%	-8.7	-	-72%	-45.0	-	-25%	-43.8	-80.6	-
Income taxes		-1.1			0.6			-3.2			-6.5			-10.2	-23.4	
Minority interests		0.0			0.0			0.0			0.0			0.2	-0.1	
Net Income	17%	6.9	-62.7%	9%	3.5	-22.7%	-16%	-5.6	-	-62%	-38.5	-	-19%	-33.7	-57.1	-
Inter-segment Transactions																
Net sales		-0.3			-0.3			-0.6			-0.4			-1.5		
Cost of sales		0.0			-0.1			-0.3			0.1			-0.3		
Gross Profit		-0.3			-0.2			-0.2			-0.5			-1.3		
SG&A expenses		1.1			1.4			1.1			1.0			4.6		
R&D expenses		-0.4			-0.3			-0.3			-0.3			-1.2		
Other expenses		1.4			1.7			1.4			1.3			5.8		
Operating Income		-1.4			-1.6			-1.3			-1.5			-5.9		
Non-operating income		-1.1			-0.1			-0.1			-0.1			-1.3		
Non-operating expenses		0.0			0.0			0.1			0.0			0.1		
Ordinary Income		-2.5			-1.7			-1.5			-1.7			-7.3		
Extraordinary income		0.1			0.0			-0.7			0.0			-0.6		
Extraordinary losses								40.3			-40.3			0.0		
Income before income taxes and minority interests		-2.4			-1.7			-42.5			38.7			-7.9		
Income taxes		-0.3			-0.2			-0.5			-0.2			-1.3		
Minority interests		2.3			1.0			-17.0			0.4			-13.4		
Net Income		-4.4			-2.4			-24.9			38.5			6.7		

4. Sales by Business Units (FY2011)

JPY Bn	Q1			Q2			Q3			Q4			FY2011		
	Results	YoY	to plan	Results	YoY	to plan	Results	YoY	to plan	Results	YoY	to plan	Results	YoY	to plan
Consolidated Net Sales	231.7	-9.7%	24%	224.4	-7.5%	23%	240.4	-3.5%	25%	242.3	+10.5%	25%	938.7	-3.0%	97%
Japan Company (domestic sales)	100.4	-4.6%	23%	100.5	-2.4%	23%	113.9	-2.4%	26%	94.9	+4.3%	22%	409.8	-1.5%	94%
Olmotec	20.4	-1.3%	22%	20.4	-3.1%	22%	22.6	-1.4%	24%	17.4	-1.2%	19%	80.9	-1.8%	87%
Rezaltas	2.9	+58.1%	17%	3.2	+393.1%	19%	3.9	+190.8%	23%	3.5	+145.4%	21%	13.5	+188.4%	79%
Calblock	3.2	-13.4%	21%	3.2	-9.4%	21%	3.3	-13.8%	22%	2.7	-7.5%	18%	12.4	-11.3%	83%
Loxonin	14.4	+10.7%	25%	15.7	+13.3%	27%	17.2	+17.6%	30%	13.7	+8.3%	24%	61.0	+12.7%	105%
Cravit	8.4	+8.5%	22%	8.4	+11.5%	22%	10.8	+16.8%	29%	8.7	+11.4%	23%	36.3	+12.3%	96%
Nexium	-	-	-	2.6	-	-	0.6	-	-	0.7	-	-	3.9	-	-
Mearny	2.2	-	-	1.6	-	-	2.8	-	-	3.2	-	-	9.8	-	-
Mevalotin	8.8	-14.0%	27%	8.6	-14.4%	27%	8.8	-11.6%	28%	6.8	-12.0%	21%	33.1	-13.1%	103%
Artist	6.1	+0.0%	27%	6.2	+6.8%	27%	6.5	+3.6%	29%	5.6	+3.7%	25%	24.5	+3.5%	107%
Omnipaque	5.7	-11.6%	25%	6.3	-5.1%	27%	6.4	-2.0%	28%	5.2	-4.5%	23%	23.5	-5.8%	102%
Urief	2.6	+6.8%	24%	2.8	+13.6%	25%	3.0	+7.6%	27%	2.6	+9.2%	23%	11.0	+9.3%	100%
Inavir	0.4	-	4%	-0.1	-	-	1.7	-38.5%	19%	8.7	+125.1%	97%	10.7	+61.7%	119%
Vaccines	4.6	+166.4%	-	5.3	+14.8%	-	6.9	-19.7%	-	4.5	+56.5%	-	21.2	+19.6%	-
Daiichi Sankyo Espha products	2.4	-	-	2.4	-	-	2.9	-	-	2.1	-	-	9.9	-	-
Daiichi Sankyo Healthcare (OTC)	9.7	+4.9%	20%	12.7	+8.2%	26%	13.7	+4.1%	28%	9.7	-8.5%	20%	45.9	+2.3%	94%
Daiichi Sankyo, Inc. (US)	34.6	+3.2%	27%	29.7	-12.4%	23%	30.1	-13.0%	23%	32.6	+15.0%	25%	127.1	-2.6%	98%
Olmesartan	24.9	-1.5%	28%	20.4	-17.4%	23%	20.6	-16.3%	23%	22.1	+10.7%	25%	87.9	-6.9%	100%
Benicar/Benicar HCT	20.1	-6.1%	30%	16.8	-18.7%	25%	16.2	-21.3%	24%	18.1	+6.6%	27%	71.3	-10.6%	106%
Azor	3.6	-7.0%	26%	2.5	-26.5%	18%	3.2	-8.7%	23%	2.8	+7.5%	21%	12.0	-9.5%	89%
Tribenzor	1.2	-	16%	1.1	+71.6%	15%	1.2	+139.2%	16%	1.1	+271.8%	15%	4.6	+217.4%	62%
Welchol	7.0	+0.5%	22%	6.5	-11.5%	20%	6.6	-16.0%	21%	6.7	+6.7%	21%	26.9	-5.8%	84%
Effient (alliance revenue)	1.6	+345.5%	-	1.7	+124.3%	-	1.9	+75.5%	-	2.8	+119.8%	-	7.9	+130.7%	-
Luitpold Pharmaceuticals, Inc. (US)	12.7	-13.6%	26%	9.3	-31.7%	19%	15.0	+31.0%	31%	7.6	-45.6%	16%	44.7	-17.0%	91%
Venofer	7.4	-12.5%	30%	5.5	-28.5%	22%	9.1	+55.6%	36%	2.9	-66.8%	12%	24.8	-19.0%	99%
Daiichi Sankyo Europe GmbH	16.9	+14.0%	22%	16.9	+2.0%	22%	17.4	-4.3%	23%	19.1	+13.0%	25%	70.2	+5.7%	91%
Olmesartan	11.9	+23.5%	22%	12.2	+4.2%	22%	12.7	-5.4%	23%	14.3	+24.4%	26%	51.0	+10.5%	93%
Olmotec/Olmotec Plus	8.7	+9.8%	22%	8.8	-5.1%	22%	9.2	-8.4%	23%	9.9	+5.4%	25%	36.6	-0.1%	92%
Sevikar	2.4	+44.1%	20%	2.6	+10.5%	22%	2.6	+13.1%	22%	3.3	+63.9%	28%	11.0	+30.9%	92%
Sevikar HCT	0.7	-	25%	0.7	-	24%	0.9	-16.6%	29%	1.1	+1296.8%	36%	3.4	+206.9%	113%
Efient (alliance revenue)	0.6	-	-	0.6	-	-	0.7	-	-	1.0	-	-	2.9	-	-
Asia, South and Central America (ASCA)	6.5	+8.7%	22%	7.3	+3.8%	24%	6.9	+2.0%	23%	7.8	+2.8%	26%	28.6	+4.1%	95%
Daiichi Sankyo Pharmaceutical (Beijing)	0.9	-19.9%	-	0.9	-15.0%	-	0.8	-28.4%	-	0.8	-11.1%	-	3.4	-18.9%	-
Daiichi Sankyo Pharmaceutical (Shanghai)	1.7	+21.9%	-	1.7	-3.8%	-	1.3	-18.7%	-	1.6	-11.3%	-	6.3	-3.9%	-
Daiichi Sankyo Taiwan	0.8	+4.6%	-	0.8	-2.8%	-	0.8	-2.7%	-	0.8	-21.0%	-	3.1	-6.3%	-
Daiichi Sankyo Korea	1.2	+23.0%	-	1.1	+27.0%	-	1.1	+14.6%	-	1.1	-0.7%	-	4.6	+15.2%	-
Daiichi Sankyo (Thailand)	0.3	+10.1%	-	0.3	+2.3%	-	0.3	-1.6%	-	0.3	-7.5%	-	1.2	-0.1%	-
Daiichi Sankyo Brasil Farmacêutica	1.1	+2.6%	-	1.5	+4.4%	-	1.5	+6.7%	-	1.5	+13.1%	-	5.5	+6.9%	-
Daiichi Sankyo Venezuela	0.5	+22.5%	-	1.0	+33.2%	-	1.1	+74.6%	-	1.6	+43.6%	-	4.2	+45.1%	-
Daiichi Sankyo Mexico S.A. de C.V	-	-	-	-	-	-	0.1	-	-	0.1	-	-	0.2	-	-
Ranbaxy Laboratories Limited	39.8	-27.5%	25%	38.4	-12.0%	24%	35.7	+0.6%	22%	61.6	+62.3%	38%	175.5	+2.1%	108%
Others	11.1	-38.7%	29%	9.5	-25.9%	25%	7.5	-40.5%	20%	8.8	-31.2%	23%	36.9	-34.5%	97%
Levofloxacin export, royalty, etc	3.1	-56.2%	45%	2.3	-67.5%	33%	1.2	-82.6%	17%	1.6	-78.3%	22%	8.1	-71.0%	116%
Plexikon	3.0	-	-	1.9	-	-	0.3	-	-	0.8	-	-	5.9	-	-

[Reference] Sales in Local Currency

	Q1			Q2			Q3			Q4			FY2011		
	Results	YoY	to plan	Results	YoY	to plan	Results	YoY	to plan	Results	YoY	to plan	Results	YoY	to plan
USD Mn															
Daiichi Sankyo, Inc. (US)	424	+16.1%	27%	382	-2.9%	24%	390	-7.5%	25%	412.0	+20.3%	26%	1,608	+5.6%	103%
Olmesartan	304	+10.9%	29%	263	-8.4%	25%	266	-11.2%	25%	278	+15.7%	26%	1,112	+0.9%	105%
Benicar/Benicar HCT	246	+5.7%	31%	217	-10.0%	27%	210	-16.5%	26%	228	+11.5%	28%	901	-3.1%	112%
Azor	43	+4.7%	27%	32	-18.4%	20%	41	-3.5%	25%	36	+11.9%	22%	152	-1.9%	94%
Tribenzor	14	-	16%	14	+96.0%	16%	15	+158.0%	17%	14	+287.9%	16%	58	+244.1%	65%
Welchol	86	+13.2%	22%	84	-1.9%	22%	85	-10.5%	22%	84	+11.6%	22%	340	+2.1%	88%
Effient (alliance revenue)	20	+401.5%	-	22	+151.6%	-	24	+90.2%	-	35	+134.1%	-	100	+150.1%	-
USD Mn															
Luitpold Pharmaceuticals, Inc. (US)	156	-2.8%	26%	121	-24.2%	21%	193	+36.4%	33%	96.0	-42.8%	16%	566	-10.0%	96%
Venofer	90	-1.5%	30%	71	-20.7%	24%	116	+60.8%	39%	36	-65.0%	12%	314	-12.2%	104%
EUR Mn															
Daiichi Sankyo Europe GmbH	144	+13.6%	21%	153	+2.7%	23%	165	+2.5%	25%	182.0	+21.5%	27%	644	+9.8%	96%
Olmesartan	101	+23.1%	21%	110	+5.1%	23%	121	+1.3%	25%	136	+33.5%	29%	468	+14.7%	98%
Olmetec/Olmetec Plus	74	+9.4%	21%	80	-4.4%	23%	88	-2.0%	25%	95	+13.4%	27%	336	+3.7%	97%
Sevikar	21	+43.7%	20%	24	+11.5%	23%	25	+21.1%	24%	32	+75.2%	30%	101	+35.9%	97%
Sevikar HCT	6	-	24%	6	-	25%	8	-10.6%	31%	10	+1366.1%	39%	31	+218.7%	119%
Efient (alliance revenue)	5	-	-	6	-	-	7	-	-	10	-	-	27	-	-
INR Bn															
Ranbaxy Laboratories Limited	22	-21.5%	26%	21	-1.5%	25%	21	+8.0%	25%	38.0	+82.4%	45%	101	+13.9%	119%

5. Sales of Global Products (FY2011)

	Q1			Q2			Q3			Q4			FY2011		
	Results	YoY	to plan	Results	YoY	to plan	Results	YoY	to plan	Results	YoY	to plan	Results	YoY	to plan
JPY Bn															
Olmesartan	63.3	+5.2%	24%	60.4	-1.6%	22%	64.2	-2.3%	24%	61.7	+13.9%	23%	249.7	+3.4%	93%
Olmetec (JPN)	20.4	-1.3%	22%	20.4	-3.1%	22%	22.6	-1.4%	24%	17.4	-1.2%	19%	80.9	-1.8%	87%
Rezaltas (JPN)	2.9	+58.1%	17%	3.2	+3938.1%	19%	3.9	+190.8%	23%	3.5	+145.4%	21%	13.5	+188.4%	79%
Benicar/Benicar HCT (US)	20.1	-6.1%	30%	16.8	-18.7%	25%	16.2	-21.3%	24%	18.1	+6.6%	27%	71.3	-10.6%	106%
Azor (US)	3.6	-7.0%	26%	2.5	-26.5%	18%	3.2	-8.7%	23%	2.8	+7.5%	21%	12.0	-9.5%	89%
Tribenzor (US)	1.2	-	16%	1.1	+71.6%	15%	1.2	+139.2%	16%	1.1	+271.8%	15%	4.6	+217.4%	62%
Olmetec/Olmetec Plus (EU)	8.7	+9.8%	22%	8.8	-5.1%	22%	9.2	-8.4%	23%	9.9	+5.4%	25%	36.6	-0.1%	92%
Sevikar (EU)	2.4	+44.1%	20%	2.6	+10.5%	22%	2.6	+13.1%	22%	3.3	+63.9%	28%	11.0	+30.9%	92%
Sevikar HCT (EU)	0.7	-	25%	0.7	-	24%	0.9	-16.6%	29%	1.1	+1296.8%	36%	3.4	+206.9%	113%
Other subsidiaries, export, etc	3.3	+16.4%	20%	4.3	+10.4%	25%	4.4	+28.8%	26%	4.5	+18.3%	26%	16.5	+18.3%	97%
Levofloxacin	13.5	-20.2%	26%	12.8	-24.1%	24%	13.9	-23.3%	26%	12.2	-29.1%	23%	52.4	-24.2%	99%
Cravit (JPN)	8.4	+8.5%	22%	8.4	+11.5%	22%	10.8	+16.8%	29%	8.7	+11.4%	23%	36.3	+12.3%	96%
Export, royalty, etc	3.1	-56.2%	45%	2.3	-67.5%	33%	1.2	-82.6%	17%	1.6	-78.3%	22%	8.1	-71.0%	116%
Other subsidiaries	2.0	-4.7%	25%	2.1	-4.9%	26%	1.9	-12.9%	23%	2.0	-11.9%	25%	7.9	-8.6%	99%
Pravastatin	10.2	-13.9%	27%	10.0	-15.5%	26%	10.6	-8.6%	28%	8.4	-12.6%	22%	39.2	-12.7%	103%
Mevalotin (JPN)	8.8	-14.0%	27%	8.6	-14.4%	27%	8.8	-11.6%	28%	6.8	-12.0%	21%	33.1	-13.1%	103%
Other subsidiaries, export, etc	1.5	-12.9%	25%	1.3	-22.1%	22%	1.7	+10.7%	29%	1.6	-15.1%	26%	6.1	-10.4%	102%
Prasugrel	2.2	+176.5%	-	2.3	+134.2%	-	2.6	+72.6%	-	3.8	+94.3%	-	10.9	+108.2%	-
Effient alliance revenue (US)	1.6	+345.5%	-	1.7	+124.3%	-	1.9	+75.5%	-	2.8	+119.8%	-	7.9	+130.7%	-
Effient alliance revenue (EU)	0.6	+34.9%	-	0.6	+165.9%	-	0.7	+65.5%	-	1.0	+47.9%	-	2.9	+64.8%	-